|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
cobamamide inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
|
G |
Cpox |
coproporphyrinogen oxidase |
decreases carboxylation multiple interactions |
ISO |
CPOX protein results in decreased carboxylation of coproporphyrinogen III Mercury inhibits the reaction [CPOX protein results in decreased carboxylation of coproporphyrinogen III] |
CTD |
PMID:19339664 |
|
NCBI chr11:44,039,665...44,049,648
Ensembl chr11:44,039,669...44,049,648
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases expression multiple interactions |
ISO |
Vitamin B 12 results in decreased expression of ABCB1 mRNA; Vitamin B 12 results in decreased expression of ABCB1 protein Vitamin B 12 inhibits the reaction [Methotrexate results in increased expression of ABCB1 mRNA] |
CTD |
PMID:17982279 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcd4 |
ATP binding cassette subfamily D member 4 |
affects metabolic processing |
ISO |
ABCD4 protein affects the metabolism of Vitamin B 12 |
CTD |
PMID:22922874 |
|
NCBI chr 6:108,315,026...108,329,550
Ensembl chr 6:108,315,035...108,329,464
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
EXP |
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in increased expression of ACACA mRNA |
CTD |
PMID:22648174 |
|
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
Vitamin B 12 inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 mRNA] |
CTD |
PMID:18239293 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
ISO |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of ALDH2 protein |
CTD |
PMID:20118189 |
|
NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
|
|
G |
As3mt |
arsenite methyltransferase |
multiple interactions |
ISO |
Folic Acid promotes the reaction [Vitamin B 12 promotes the reaction [AS3MT protein results in increased methylation of Arsenic]]; Vitamin B 12 promotes the reaction [AS3MT protein results in increased methylation of Arsenic] |
CTD |
PMID:20049124 |
|
NCBI chr 1:266,482,787...266,514,570
Ensembl chr 1:266,482,858...266,514,569
|
|
G |
Axin1 |
axin 1 |
multiple interactions |
ISO |
[Folic Acid co-treated with Vitamin B 12 co-treated with Betaine co-treated with Choline] results in increased methylation of AXIN1 gene |
CTD |
PMID:16868943 |
|
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
Folic Acid inhibits the reaction [Vitamin B 12 promotes the reaction [Dietary Fats results in increased expression of CASP3 mRNA]]; Vitamin B 12 promotes the reaction [Dietary Fats results in increased expression of CASP3 mRNA] |
CTD |
PMID:23935743 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
EXP |
Folic Acid inhibits the reaction [Vitamin B 12 promotes the reaction [Dietary Fats results in increased expression of CASP8 mRNA]]; Vitamin B 12 promotes the reaction [Dietary Fats results in increased expression of CASP8 mRNA] |
CTD |
PMID:23935743 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cat |
catalase |
multiple interactions |
ISO EXP |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased activity of CAT protein Vitamin B 12 promotes the reaction [Folic Acid inhibits the reaction [arsenic trioxide results in decreased activity of CAT protein]] |
CTD |
PMID:16214333 PMID:20118189 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cbs |
cystathionine beta synthase |
multiple interactions |
EXP |
[Fatty Acids, Omega-3 co-treated with Folic Acid co-treated with Vitamin B 12 deficiency] results in increased expression of CBS mRNA; [Fatty Acids, Omega-3 co-treated with Vitamin B 12 deficiency] results in increased expression of CBS mRNA; [Folic Acid co-treated with Vitamin B 12 deficiency] results in increased expression of CBS mRNA |
CTD |
PMID:25003120 |
|
NCBI chr20:10,361,987...10,386,663
Ensembl chr20:10,361,988...10,386,751
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with Dietary Fats co-treated with Dietary Sucrose] results in decreased expression of CCL2 mRNA |
CTD |
PMID:22648174 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
[Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in decreased expression of CD40 mRNA |
CTD |
PMID:30116142 |
|
NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
ISO |
[Folic Acid co-treated with Riboflavin co-treated with Vitamin B 6 co-treated with Vitamin B 12] results in decreased expression of CRP protein; [Vitamin E co-treated with Ascorbic Acid co-treated with Folic Acid co-treated with Riboflavin co-treated with Vitamin B 6 co-treated with Vitamin B 12] results in decreased expression of CRP protein |
CTD |
PMID:16517955 |
|
NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate] inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein] |
CTD |
PMID:20118189 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Fads1 |
fatty acid desaturase 1 |
multiple interactions |
EXP |
[Fatty Acids, Omega-3 co-treated with Vitamin B 12 deficiency] results in decreased expression of FADS1 mRNA; [Folic Acid co-treated with Vitamin B 12 deficiency] results in decreased expression of FADS1 mRNA; [Vitamin B 12 deficiency co-treated with Fatty Acids, Omega-3] results in decreased activity of FADS1 protein; Folic Acid inhibits the reaction [[Fatty Acids, Omega-3 co-treated with Vitamin B 12 deficiency] results in decreased expression of FADS1 mRNA]; Folic Acid promotes the reaction [[Vitamin B 12 deficiency co-treated with Fatty Acids, Omega-3] results in decreased activity of FADS1 protein]; Vitamin B 12 deficiency promotes the reaction [Folic Acid results in increased activity of FADS1 protein] |
CTD |
PMID:22133376 |
|
NCBI chr 1:226,234,034...226,249,118
Ensembl chr 1:226,234,074...226,249,138
|
|
G |
Fads2 |
fatty acid desaturase 2 |
multiple interactions |
EXP |
[Vitamin B 12 deficiency co-treated with Fatty Acids, Omega-3] results in decreased activity of FADS2 protein; [Vitamin B 12 deficiency co-treated with Folic Acid] results in decreased activity of FADS2 protein; Folic Acid inhibits the reaction [[Vitamin B 12 deficiency co-treated with Fatty Acids, Omega-3] results in decreased activity of FADS2 protein] |
CTD |
PMID:22133376 |
|
NCBI chr 1:225,906,582...226,152,568
Ensembl chr 1:226,114,413...226,152,524
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
EXP |
[Choline co-treated with Betaine co-treated with Vitamin B 12 co-treated with Folic Acid] affects the reaction [[Dietary Fats co-treated with Dietary Sucrose] affects the methylation of FASN promoter] |
CTD |
PMID:22648174 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Folh1 |
folate hydrolase 1 |
multiple interactions |
ISO |
Vitamin B 12 affects the reaction [FOLH1 gene SNP affects the susceptibility to and affects the metabolism of Arsenic] |
CTD |
PMID:29459232 |
|
NCBI chr 1:150,323,768...150,395,415
Ensembl chr 1:150,323,768...150,395,415
|
|
G |
Fut2 |
fucosyltransferase 2 |
affects abundance |
ISO |
FUT2 gene polymorphism affects the abundance of Vitamin B 12 |
CTD |
PMID:18776911 |
|
NCBI chr 1:101,631,633...101,651,668
Ensembl chr 1:101,631,635...101,651,668
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions |
ISO |
3-(4-Amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine promotes the reaction [Vitamin B 12 results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Vitamin B 12 results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein] |
CTD |
PMID:22171090 |
|
NCBI chr 2:181,045,694...181,103,321
Ensembl chr 2:181,045,703...181,102,918
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO |
3-(4-Amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine promotes the reaction [Vitamin B 12 results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Vitamin B 12 results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein] |
CTD |
PMID:22171090 |
|
NCBI chr 2:180,976,939...181,026,001
Ensembl chr 2:180,976,939...181,026,024
|
|
G |
Hba-a2 |
hemoglobin alpha, adult chain 2 |
affects expression affects glycosylation |
ISO |
Vitamin B 12 affects the expression of HBA1 protein modified form Vitamin B 12 affects the glycosylation of HBA1 protein |
CTD |
PMID:2299304 |
|
NCBI chr10:15,589,364...15,590,207
Ensembl chr10:15,589,364...15,590,220
|
|
G |
Il1b |
interleukin 1 beta |
increases methylation multiple interactions |
ISO |
Vitamin B 12 results in increased methylation of IL1B gene [Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in decreased expression of IL1B mRNA; [Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in decreased secretion of IL1B protein; [Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased methylation of IL1B gene |
CTD |
PMID:30116142 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
[Folic Acid co-treated with Vitamin B 12] inhibits the reaction [arsenic trioxide results in increased expression of IL6 protein] |
CTD |
PMID:16214333 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Maob |
monoamine oxidase B |
decreases activity |
ISO |
Vitamin B 12 results in decreased activity of MAOB protein |
CTD |
PMID:7430361 |
|
NCBI chr X:6,430,694...6,533,520
Ensembl chr X:6,430,594...6,533,534
|
|
G |
Mat2a |
methionine adenosyltransferase 2A |
multiple interactions |
EXP |
[Fatty Acids, Omega-3 co-treated with Vitamin B 12 deficiency] results in increased expression of MAT2A mRNA; [Folic Acid co-treated with Vitamin B 12 deficiency] results in increased expression of MAT2A mRNA; Fatty Acids, Omega-3 promotes the reaction [[Folic Acid co-treated with Vitamin B 12 deficiency] results in increased expression of MAT2A mRNA] |
CTD |
PMID:25003120 |
|
NCBI chr 4:100,297,478...100,303,047
Ensembl chr 4:100,296,075...100,303,080
|
|
G |
Mmachc |
metabolism of cobalamin associated C |
increases metabolic processing affects binding decreases metabolic processing |
ISO |
MMACHC protein results in increased metabolism of Vitamin B 12 Vitamin B 12 analog binds to MMACHC protein; Vitamin B 12 binds to MMACHC protein MMACHC protein mutant form results in decreased metabolism of Vitamin B 12 |
CTD |
PMID:19700356 |
|
NCBI chr 5:135,555,587...135,561,723
Ensembl chr 5:135,555,565...135,561,914
|
|
G |
Mthfr |
methylenetetrahydrofolate reductase |
decreases expression multiple interactions |
EXP |
Vitamin B 12 deficiency results in decreased expression of MTHFR mRNA [Folic Acid co-treated with Vitamin B 12 deficiency] results in decreased expression of MTHFR mRNA; Fatty Acids, Omega-3 inhibits the reaction [Vitamin B 12 deficiency results in decreased expression of MTHFR mRNA] |
CTD |
PMID:25003120 |
|
NCBI chr 5:164,844,642...164,864,360
Ensembl chr 5:164,845,925...164,860,910
|
|
G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
affects binding multiple interactions increases activity |
ISO EXP |
Vitamin B 12 binds to MTR protein [Fatty Acids, Omega-3 co-treated with Vitamin B 12 deficiency] results in decreased expression of MTR mRNA; Fatty Acids, Omega-3 promotes the reaction [Vitamin B 12 deficiency inhibits the reaction [Fatty Acids, Omega-3 results in increased expression of MTR mRNA]]; Vitamin B 12 deficiency inhibits the reaction [Fatty Acids, Omega-3 results in increased expression of MTR mRNA] Vitamin B 12 results in increased activity of MTR protein |
CTD |
PMID:17477549 PMID:17982279 PMID:25003120 |
|
NCBI chr17:66,210,444...66,295,014
Ensembl chr17:66,210,461...66,295,014
|
|
G |
Pemt |
phosphatidylethanolamine N-methyltransferase |
multiple interactions |
EXP |
[Fatty Acids, Omega-3 co-treated with Vitamin B 12 deficiency] results in increased expression of PEMT mRNA; [Folic Acid co-treated with Vitamin B 12 deficiency] results in increased expression of PEMT mRNA; Fatty Acids, Omega-3 inhibits the reaction [[Folic Acid co-treated with Vitamin B 12 deficiency] results in increased expression of PEMT mRNA] |
CTD |
PMID:25003120 |
|
NCBI chr10:46,339,821...46,404,640
Ensembl chr10:46,339,821...46,404,642
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[Betaine co-treated with Choline co-treated with Folic Acid co-treated with Methionine co-treated with Vitamin B 12 co-treated with Zinc Sulfate co-treated with Ethanol] results in increased expression of PPARA protein |
CTD |
PMID:20118189 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP |
[Folic Acid co-treated with Vitamin B 12] inhibits the reaction [Dietary Fats results in decreased expression of PPARG mRNA]; Vitamin B 12 inhibits the reaction [Dietary Fats results in decreased expression of PPARG mRNA] |
CTD |
PMID:23935743 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions increases methylation |
ISO |
[Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SERPINE1 mRNA; [Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased methylation of SERPINE1 gene Vitamin B 12 results in increased methylation of SERPINE1 gene |
CTD |
PMID:30116142 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Serpinh1 |
serpin family H member 1 |
multiple interactions |
ISO |
Vitamin B 12 inhibits the reaction [Dimethylnitrosamine results in increased expression of SERPINH1 mRNA] |
CTD |
PMID:18239293 |
|
NCBI chr 1:164,301,010...164,308,306
Ensembl chr 1:164,301,010...164,308,317
|
|
G |
Tcn2 |
transcobalamin 2 |
multiple interactions |
ISO |
TCN2 protein binds to and results in increased uptake of Vitamin B 12 |
CTD |
PMID:14632784 |
|
NCBI chr14:84,173,992...84,189,299
Ensembl chr14:84,174,138...84,189,266
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
[Folic Acid co-treated with Vitamin B 12] inhibits the reaction [arsenic trioxide results in increased expression of TNF protein] [Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in decreased expression of TNF mRNA; [Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in decreased secretion of TNF protein |
CTD |
PMID:16214333 PMID:30116142 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
increases expression |
ISO |
Heme results in increased expression of ABCB6 mRNA; Heme results in increased expression of ABCB6 protein |
CTD |
PMID:17006453 |
|
NCBI chr 9:82,373,950...82,382,228
Ensembl chr 9:82,373,946...82,382,272
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
increases expression |
ISO |
Heme metabolite results in increased expression of ADRA1A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:43,296,997...43,398,314
Ensembl chr15:43,298,794...43,392,451
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
decreases expression multiple interactions |
ISO |
Heme results in decreased expression of ALAS1 protein MG 262 inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; Protease Inhibitors inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; succinylacetone inhibits the reaction [Heme results in decreased expression of ALAS1 protein] |
CTD |
PMID:21659532 |
|
NCBI chr 8:114,927,704...114,941,038
Ensembl chr 8:114,927,722...114,940,177
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ALAS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:23,167,576...23,187,356
Ensembl chr X:23,167,696...23,187,341
|
|
G |
Alb |
albumin |
affects binding multiple interactions |
ISO |
Heme binds to ALB protein abacavir inhibits the reaction [Heme binds to ALB protein]; Heme inhibits the reaction [abacavir binds to ALB protein] |
CTD |
PMID:16336266 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Ambp |
alpha-1-microglobulin/bikunin precursor |
increases expression |
ISO |
Heme results in increased expression of AMBP mRNA |
CTD |
PMID:22096585 |
|
NCBI chr 5:78,975,690...78,986,021
Ensembl chr 5:78,975,678...78,985,990
|
|
G |
App |
amyloid beta precursor protein |
affects binding multiple interactions |
ISO |
APP protein modified form binds to Heme [Hydrogen Peroxide co-treated with Sodium Nitrite] promotes the reaction [APP protein modified form binds to Heme]; Hydrogen Peroxide promotes the reaction [APP protein modified form binds to Heme] |
CTD |
PMID:25211009 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Arhgap31 |
Rho GTPase activating protein 31 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ARHGAP31 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:64,600,968...64,714,114
Ensembl chr11:64,601,029...64,714,252
|
|
G |
Asb1 |
ankyrin repeat and SOCS box-containing 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of ASB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:98,668,231...98,689,471
Ensembl chr 9:98,668,231...98,684,900
|
|
G |
Asxl2 |
ASXL transcriptional regulator 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ASXL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:27,835,346...27,919,285
Ensembl chr 6:27,887,797...27,915,563
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions |
ISO |
ATP7B gene mutant form promotes the reaction [Copper results in decreased abundance of Heme] |
CTD |
PMID:19888908 |
|
NCBI chr16:74,865,516...74,944,935
Ensembl chr16:74,865,516...74,945,286
|
|
G |
Bcar3 |
BCAR3 adaptor protein, NSP family member |
increases expression |
ISO |
Heme metabolite results in increased expression of BCAR3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:226,563,050...226,679,449
Ensembl chr 2:226,563,050...226,679,438
|
|
G |
Blvra |
biliverdin reductase A |
increases expression |
ISO |
Heme metabolite results in increased expression of BLVRA mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:119,552,550...119,577,796
Ensembl chr 3:119,561,290...119,577,806
|
|
G |
Bok |
BCL2 family apoptosis regulator BOK |
decreases expression |
ISO |
Heme metabolite results in decreased expression of BOK mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:100,829,593...100,840,498
Ensembl chr 9:100,829,552...100,840,504
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CAMK2B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:86,208,876...86,297,727
Ensembl chr14:86,208,901...86,297,652
|
|
G |
Camk2g |
calcium/calmodulin-dependent protein kinase II gamma |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CAMK2G mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:3,936,721...3,995,740
Ensembl chr15:3,936,786...3,995,915
|
|
G |
Car1 |
carbonic anhydrase 1 |
multiple interactions increases expression |
EXP |
[Heme co-treated with Calcium, Dietary] results in increased expression of CAR1 mRNA Heme results in increased expression of CAR1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:88,185,204...88,227,486
Ensembl chr 2:88,217,188...88,227,479
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of CCL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases secretion |
ISO |
Heme analog results in increased secretion of CCL3 protein |
CTD |
PMID:23355332 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccl6 |
C-C motif chemokine ligand 6 |
increases expression |
ISO |
Heme metabolite results in increased expression of CCL6 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:70,798,118...70,802,750
Ensembl chr10:70,797,124...70,802,782
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
multiple interactions |
ISO |
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein] |
CTD |
PMID:19039664 |
|
NCBI chr 1:220,075,251...220,096,319
Ensembl chr 1:220,075,247...220,096,404
|
|
G |
Cd2 |
Cd2 molecule |
increases expression |
ISO |
Heme metabolite results in increased expression of CD2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:203,666,706...203,680,073
Ensembl chr 2:203,666,637...203,680,083
|
|
G |
Cel |
carboxyl ester lipase |
decreases expression multiple interactions |
EXP |
Heme results in decreased expression of CEL mRNA [Heme co-treated with Calcium, Dietary] results in decreased expression of CEL mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 3:7,134,021...7,141,522
Ensembl chr 3:7,134,021...7,141,522
|
|
G |
Clca1 |
chloride channel accessory 1 |
decreases expression |
EXP |
Heme results in decreased expression of CLCA1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:250,897,980...250,923,711
Ensembl chr 2:250,897,969...250,923,744
|
|
G |
Cnot9 |
CCR4-NOT transcription complex subunit 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of CNOT9 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:81,783,349...81,808,815
Ensembl chr 9:81,783,349...81,808,805
|
|
G |
Cops5 |
COP9 signalosome subunit 5 |
increases expression |
ISO |
Heme metabolite results in increased expression of COPS5 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:8,876,090...8,894,345
Ensembl chr 5:8,876,044...8,894,339
|
|
G |
Cpox |
coproporphyrinogen oxidase |
increases chemical synthesis |
ISO |
CPOX protein results in increased chemical synthesis of Heme |
CTD |
PMID:11248690 |
|
NCBI chr11:44,039,665...44,049,648
Ensembl chr11:44,039,669...44,049,648
|
|
G |
Csf2 |
colony stimulating factor 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CSF2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of CXCL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr18:81,694,818...81,726,821
Ensembl chr18:81,694,808...81,726,821
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Dgcr8 |
DGCR8 microprocessor complex subunit |
affects binding |
ISO |
DGCR8 protein binds to Heme; DGCR8 protein mutant form binds to Heme |
CTD |
PMID:21454614 |
|
NCBI chr11:86,852,682...86,885,233
Ensembl chr11:86,852,711...86,885,224
|
|
G |
Dnajc7 |
DnaJ heat shock protein family (Hsp40) member C7 |
decreases expression |
EXP |
Heme results in decreased expression of DNAJC7 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr10:88,498,271...88,533,730
Ensembl chr10:88,498,238...88,533,829
|
|
G |
Dner |
delta/notch-like EGF repeat containing |
decreases expression |
ISO |
Heme metabolite results in decreased expression of DNER mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:91,965,866...92,291,172
Ensembl chr 9:91,965,866...92,291,220
|
|
G |
Dusp14 |
dual specificity phosphatase 14 |
increases expression |
ISO |
Heme metabolite results in increased expression of DUSP14 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:71,363,688...71,383,602
Ensembl chr10:71,363,688...71,383,602
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of DUSP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:119,776,925...119,779,110
Ensembl chr 3:119,776,925...119,779,099
|
|
G |
Eif2s3 |
eukaryotic translation initiation factor 2 subunit gamma |
decreases expression |
ISO |
Heme metabolite results in decreased expression of EIF2S3X mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:63,268,106...63,291,125
Ensembl chr X:63,268,037...63,292,092
|
|
G |
Eno2 |
enolase 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of ENO2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Heme metabolite results in increased expression of EREG mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:18,577,620...18,591,395
Ensembl chr14:18,576,355...18,591,394
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ESRRA mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:222,168,729...222,178,842
Ensembl chr 1:222,168,730...222,178,725
|
|
G |
F10 |
coagulation factor X |
increases expression |
ISO |
Heme metabolite results in increased expression of F10 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:81,803,169...81,822,476
Ensembl chr16:81,803,110...81,822,716
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression multiple interactions |
ISO |
Heme results in increased expression of F3 mRNA Curcumin inhibits the reaction [Heme results in increased expression of F3 mRNA]; Heme results in increased expression of and results in increased activity of F3 protein; Sulfasalazine inhibits the reaction [Heme results in increased expression of F3 mRNA] |
CTD |
PMID:18983524 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fabp2 |
fatty acid binding protein 2 |
multiple interactions increases expression |
EXP |
[Heme co-treated with Calcium, Dietary] results in increased expression of FABP2 mRNA Heme results in increased expression of FABP2 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:227,080,912...227,083,654
Ensembl chr 2:227,080,924...227,083,501
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of FABP3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:148,528,854...148,535,597
Ensembl chr 5:148,528,725...148,535,565
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
Heme metabolite results in decreased expression of FOS mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fxyd4 |
FXYD domain-containing ion transport regulator 4 |
decreases expression |
EXP |
Heme results in decreased expression of FXYD4 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 4:149,984,206...149,988,744
Ensembl chr 4:149,984,206...149,988,295
|
|
G |
Gfod1 |
glucose-fructose oxidoreductase domain containing 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of GFOD1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:23,818,370...23,924,393
Ensembl chr17:23,823,632...23,923,792
|
|
G |
Gipc1 |
GIPC PDZ domain containing family, member 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of GIPC1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr19:24,786,604...24,798,231
Ensembl chr19:24,786,628...24,798,233
|
|
G |
Gpr176 |
G protein-coupled receptor 176 |
increases expression |
ISO |
Heme metabolite results in increased expression of GPR176 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:110,042,853...110,140,756
Ensembl chr 3:110,042,853...110,140,756
|
|
G |
Gprc5a |
G protein-coupled receptor, class C, group 5, member A |
increases expression |
ISO |
Heme metabolite results in increased expression of GPRC5A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:168,832,937...168,851,650
Ensembl chr 4:168,832,910...168,851,652
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases expression |
ISO |
Heme metabolite results in increased expression of GPT mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions |
EXP |
5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]] |
CTD |
PMID:19466990 |
|
NCBI chr 2:181,045,694...181,103,321
Ensembl chr 2:181,045,703...181,102,918
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO EXP |
Polysorbates inhibits the reaction [Heme binds to GUCY1B1 protein] 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]] |
CTD |
PMID:19466990 PMID:22171090 |
|
NCBI chr 2:180,976,939...181,026,001
Ensembl chr 2:180,976,939...181,026,024
|
|
G |
Hectd3 |
HECT domain E3 ubiquitin protein ligase 3 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of HECTD3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:135,860,578...135,870,535
Ensembl chr 5:135,860,675...135,868,495
|
|
G |
Hk3 |
hexokinase 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of HK3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:10,134,726...10,152,976
Ensembl chr17:10,137,974...10,152,956
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases degradation increases metabolic processing decreases expression decreases abundance increases expression |
ISO EXP |
[HMOX1 protein results in increased degradation of Heme] which results in increased abundance of Iron; NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA]; SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] HMOX1 protein results in increased metabolism of Heme Heme results in decreased expression of HMOX1 mRNA HMOX1 protein results in decreased abundance of Heme [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; HMOX1 enhancer affects the reaction [Heme results in increased expression of HMOX1 mRNA]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] Heme analog results in increased expression of HMOX1 protein; Heme results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 protein Heme metabolite results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 mRNA [stannous chloride results in increased activity of HMOX1 protein] which results in decreased abundance of Heme; Heme promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of and results in increased activity of HMOX1 protein] |
CTD |
PMID:7538129 PMID:8630002 PMID:9224953 PMID:10874044 PMID:12783778 PMID:15242350 PMID:16959961 PMID:17156779 PMID:17292349 PMID:18178725 PMID:19039664 PMID:19136476 PMID:19191707 PMID:19952508 PMID:20638379 PMID:22859313 PMID:32671443 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hpx |
hemopexin |
multiple interactions affects binding |
ISO |
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; [Heme co-treated with HPX protein] affects the activity of MT1 promoter; [Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein]; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; Copper inhibits the reaction [Heme binds to HPX protein]; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] |
CTD |
PMID:11213479 PMID:19039664 |
|
NCBI chr 1:170,423,558...170,431,066
Ensembl chr 1:170,423,483...170,431,073
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] |
CTD |
PMID:11076874 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Heme metabolite results in increased expression of IL1A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] Heme analog results in increased secretion of IL1B protein |
CTD |
PMID:11076874 PMID:23355332 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of IL1RL1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:47,133,483...47,184,316
Ensembl chr 9:47,134,034...47,182,170
|
|
G |
Il20 |
interleukin 20 |
increases expression |
ISO |
Heme metabolite results in increased expression of IL20 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:47,644,071...47,651,487
Ensembl chr13:47,644,071...47,647,715
|
|
G |
Il7r |
interleukin 7 receptor |
increases expression |
ISO |
Heme metabolite results in increased expression of IL7R mRNA |
CTD |
PMID:19191707 |
|
|
|
G |
Irf3 |
interferon regulatory factor 3 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of IRF3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:100,992,244...100,997,202
Ensembl chr 1:100,992,405...100,997,198
|
|
G |
Irf4 |
interferon regulatory factor 4 |
increases expression |
ISO |
Heme metabolite results in increased expression of IRF4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:34,886,746...34,905,191
Ensembl chr17:34,886,739...34,905,117
|
|
G |
Itln1 |
intelectin 1 |
decreases expression |
EXP |
Heme results in decreased expression of ITLN1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr13:89,919,570...89,929,774
Ensembl chr13:89,919,667...89,929,770
|
|
G |
Krt20 |
keratin 20 |
increases expression |
EXP |
Heme results in increased expression of KRT20 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr10:87,342,514...87,351,045
Ensembl chr10:87,342,619...87,351,045
|
|
G |
Lep |
leptin |
multiple interactions increases abundance |
ISO |
cobaltiprotoporphyrin inhibits the reaction [LEP gene mutant form results in increased abundance of Heme]; tin mesoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [LEP gene mutant form results in increased abundance of Heme]] |
CTD |
PMID:23839791 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
LOC100364500 |
RT1 class I, locus CE11-like |
decreases expression |
ISO |
Heme metabolite results in decreased expression of H2-Q1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:2,704,153...2,707,111
Ensembl chr20:2,704,148...2,707,120
|
|
G |
Lyz2 |
lysozyme 2 |
multiple interactions increases secretion |
ISO |
SB 203580 inhibits the reaction [Heme analog results in increased secretion of LYZ protein] |
CTD |
PMID:23355332 |
|
NCBI chr 7:60,335,968...60,341,264
Ensembl chr 7:60,335,969...60,341,264
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Heme inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:17292349 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mptx1 |
mucosal pentraxin 1 |
decreases expression multiple interactions |
EXP |
Heme results in decreased expression of MPTX1 mRNA Calcium, Dietary inhibits the reaction [Heme results in decreased expression of MPTX1 mRNA] |
CTD |
PMID:15539406 |
|
NCBI chr13:91,772,927...91,827,231
Ensembl chr13:91,773,004...91,776,397
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
decreases expression |
ISO |
Heme metabolite results in decreased expression of MRE11A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:13,304,355...13,350,329
Ensembl chr 8:13,305,152...13,352,489
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions decreases response to substance |
ISO |
[Heme co-treated with HPX protein] affects the activity of MT1 promoter MT1A protein results in decreased susceptibility to Heme |
CTD |
PMID:11213479 PMID:11878821 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mtf1 |
metal-regulatory transcription factor 1 |
multiple interactions |
ISO |
[Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein] |
CTD |
PMID:11213479 |
|
NCBI chr 5:142,797,340...142,843,896
Ensembl chr 5:142,797,366...142,842,122
|
|
G |
Mtmr10 |
myotubularin related protein 10 |
increases expression |
ISO |
Heme metabolite results in increased expression of MTMR10 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:125,124,743...125,175,857
Ensembl chr 1:125,124,743...125,175,857
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions |
ISO |
NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA] |
CTD |
PMID:10874044 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
affects localization |
ISO |
Heme analog affects the localization of NFKB1 protein |
CTD |
PMID:23355332 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Heme analog results in increased phosphorylation of and results in increased degradation of NFKBIA protein |
CTD |
PMID:23355332 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Ngb |
neuroglobin |
affects binding |
ISO |
Carbon Dioxide binds to [Heme binds to NGB protein]; Heme binds to NGB protein |
CTD |
PMID:16684569 |
|
NCBI chr 6:111,126,259...111,131,699
Ensembl chr 6:111,126,261...111,132,320
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] |
CTD |
PMID:11076874 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Pars2 |
prolyl-tRNA synthetase 2, mitochondrial |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PARS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:126,254,090...126,259,204
Ensembl chr 5:126,254,142...126,259,200
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PCSK2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:137,618,891...137,923,385
Ensembl chr 3:137,618,898...137,925,605
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PDGFB mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:121,215,458...121,233,092
Ensembl chr 7:121,214,628...121,232,741
|
|
G |
Pgap2 |
post-GPI attachment to proteins 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PGAP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:167,309,021...167,335,550
Ensembl chr 1:167,309,051...167,334,741
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PHLDA1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:54,247,460...54,249,664
Ensembl chr 7:54,247,460...54,249,664
|
|
G |
Pja2 |
praja ring finger ubiquitin ligase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PJA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:111,998,204...112,048,847
Ensembl chr 9:111,998,203...112,027,240
|
|
G |
Plekhm1 |
pleckstrin homology and RUN domain containing M1 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLEKHM1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:91,451,890...91,500,675
Ensembl chr10:91,451,865...91,500,661
|
|
G |
Plekho1 |
pleckstrin homology domain containing O1 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLEKHO1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:198,112,104...198,120,202
Ensembl chr 2:198,112,076...198,120,120
|
|
G |
Plk2 |
polo-like kinase 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLK2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:41,911,143...41,916,901
Ensembl chr 2:41,911,131...41,916,901
|
|
G |
Plxna2 |
plexin A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLXNA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:113,373,569...113,570,774
Ensembl chr13:113,373,578...113,571,648
|
|
G |
Pomt1 |
protein-O-mannosyltransferase 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of POMT1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:11,253,424...11,271,873
Ensembl chr 3:11,254,026...11,271,872
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
|
|
G |
Ppie |
peptidylprolyl isomerase E |
increases expression |
ISO |
Heme metabolite results in increased expression of PPIE mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:140,822,141...140,835,244
Ensembl chr 5:140,822,141...140,834,959
|
|
G |
Pstpip2 |
proline-serine-threonine phosphatase-interacting protein 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PSTPIP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:74,173,809...74,291,188
Ensembl chr18:74,174,936...74,292,921
|
|
G |
Rab33a |
RAB33A, member RAS oncogene family |
increases expression |
ISO |
Heme metabolite results in increased expression of RAB33A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:135,348,799...135,360,204
Ensembl chr X:135,348,436...135,360,203
|
|
G |
Rab3a |
RAB3A, member RAS oncogene family |
decreases expression |
ISO |
Heme metabolite results in decreased expression of RAB3A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:20,435,098...20,439,206
Ensembl chr16:20,435,101...20,439,206
|
|
G |
Rbm39 |
RNA binding motif protein 39 |
increases expression |
ISO |
Heme metabolite results in increased expression of RBM39 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:151,691,498...151,724,723
Ensembl chr 3:151,691,514...151,724,654
|
|
G |
Rbx1 |
ring-box 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of RBX1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:122,700,849...122,710,907
Ensembl chr 7:122,700,854...122,709,935
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization |
ISO |
Heme analog affects the localization of RELA protein |
CTD |
PMID:23355332 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Rhebl1 |
RHEB like 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of RHEBL1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:140,552,704...140,556,980
Ensembl chr 7:140,552,733...140,556,639
|
|
G |
Rpap1 |
RNA polymerase II associated protein 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of RPAP1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:111,565,646...111,587,184
Ensembl chr 3:111,565,650...111,587,151
|
|
G |
Rps6ka2 |
ribosomal protein S6 kinase A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of RPS6KA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:53,219,346...53,499,445
Ensembl chr 1:53,360,157...53,499,445
|
|
G |
RT1-Bb |
RT1 class II, locus Bb |
decreases expression |
ISO |
Heme metabolite results in decreased expression of H2-AB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:4,043,726...4,049,367
Ensembl chr20:4,039,413...4,049,711
|
|
G |
RT1-S3 |
RT1 class Ib, locus S3 |
increases expression |
ISO |
Heme metabolite results in increased expression of H2-T23 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:3,176,124...3,180,825
Ensembl chr20:3,176,107...3,179,818
|
|
G |
Setdb1 |
SET domain bifurcated histone lysine methyltransferase 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SETDB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:196,495,867...196,527,412
Ensembl chr 2:196,495,867...196,527,127
|
|
G |
Slamf7 |
SLAM family member 7 |
increases expression |
ISO |
Heme metabolite results in increased expression of SLAMF7 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:90,056,726...90,075,159
Ensembl chr13:90,058,127...90,075,144
|
|
G |
Slc46a1 |
solute carrier family 46 member 1 |
multiple interactions increases uptake |
ISO |
SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] SLC46A1 protein results in increased uptake of Heme |
CTD |
PMID:17156779 |
|
NCBI chr10:65,728,508...65,741,708
Ensembl chr10:65,733,991...65,740,828
|
|
G |
Smarcb1 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SMARCB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:13,679,955...13,702,821
Ensembl chr20:13,680,716...13,704,931
|
|
G |
Smc4 |
structural maintenance of chromosomes 4 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SMC4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:165,600,934...165,629,415
Ensembl chr 2:165,601,007...165,629,415
|
|
G |
Srp9 |
signal recognition particle 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of SRP9 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:100,551,307...100,559,447
Ensembl chr13:100,551,307...100,559,447
|
|
G |
Stard4 |
StAR-related lipid transfer domain containing 4 |
increases expression |
ISO |
Heme metabolite results in increased expression of STARD4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:25,982,210...25,997,555
Ensembl chr18:25,984,638...25,997,555
|
|
G |
Taf7 |
TATA-box binding protein associated factor 7 |
increases expression |
ISO |
Heme metabolite results in increased expression of TAF7 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:30,779,149...30,781,297
Ensembl chr18:30,779,150...30,781,292
|
|
G |
Tdo2 |
tryptophan 2,3-dioxygenase |
multiple interactions |
EXP |
Heme promotes the reaction [pyridine results in increased activity of TDO2 protein] |
CTD |
PMID:10413312 |
|
NCBI chr 2:180,897,059...180,914,919
Ensembl chr 2:180,897,011...180,914,940
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] Heme analog results in increased secretion of TNF protein |
CTD |
PMID:11076874 PMID:23355332 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfsf13b |
TNF superfamily member 13b |
decreases expression |
ISO |
Heme metabolite results in decreased expression of TNFSF13B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:85,275,690...85,306,419
Ensembl chr16:85,275,678...85,306,366
|
|
G |
Tollip |
toll interacting protein |
increases expression |
ISO |
Heme metabolite results in increased expression of TOLLIP mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:214,823,993...214,844,861
Ensembl chr 1:214,823,978...214,844,858
|
|
G |
Tuba4a |
tubulin, alpha 4A |
increases expression |
ISO |
Heme metabolite results in increased expression of TUBA4A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:82,415,599...82,419,918
Ensembl chr 9:82,415,605...82,419,288
|
|
G |
Ube2l3 |
ubiquitin-conjugating enzyme E2L 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of UBE2L3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:88,047,186...88,088,477
Ensembl chr11:88,047,832...88,088,476
|
|
G |
Ube2r2 |
ubiquitin-conjugating enzyme E2R 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of UBE2R2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:57,472,315...57,530,973
Ensembl chr 5:57,472,315...57,530,987
|
|
G |
Wfikkn2 |
WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of WFIKKN2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:81,936,156...81,943,142
Ensembl chr10:81,936,444...81,942,188
|
|
G |
Yeats2 |
YEATS domain containing 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of YEATS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:84,330,064...84,595,296
Ensembl chr11:84,330,064...84,583,542
|
|
|
G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
multiple interactions |
ISO |
[glutathionylcobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form |
CTD |
PMID:26989453 |
|
NCBI chr17:66,210,444...66,295,014
Ensembl chr17:66,210,461...66,295,014
|
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
increases expression |
ISO |
Heme results in increased expression of ABCB6 mRNA; Heme results in increased expression of ABCB6 protein |
CTD |
PMID:17006453 |
|
NCBI chr 9:82,373,950...82,382,228
Ensembl chr 9:82,373,946...82,382,272
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
increases expression |
ISO |
Heme metabolite results in increased expression of ADRA1A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:43,296,997...43,398,314
Ensembl chr15:43,298,794...43,392,451
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
multiple interactions decreases expression |
ISO |
MG 262 inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; Protease Inhibitors inhibits the reaction [Heme results in decreased expression of ALAS1 protein]; succinylacetone inhibits the reaction [Heme results in decreased expression of ALAS1 protein] |
CTD |
PMID:21659532 |
|
NCBI chr 8:114,927,704...114,941,038
Ensembl chr 8:114,927,722...114,940,177
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ALAS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:23,167,576...23,187,356
Ensembl chr X:23,167,696...23,187,341
|
|
G |
Alb |
albumin |
multiple interactions affects binding |
ISO |
abacavir inhibits the reaction [Heme binds to ALB protein]; Heme inhibits the reaction [abacavir binds to ALB protein] |
CTD |
PMID:16336266 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Ambp |
alpha-1-microglobulin/bikunin precursor |
increases expression |
ISO |
Heme results in increased expression of AMBP mRNA |
CTD |
PMID:22096585 |
|
NCBI chr 5:78,975,690...78,986,021
Ensembl chr 5:78,975,678...78,985,990
|
|
G |
App |
amyloid beta precursor protein |
affects binding multiple interactions |
ISO |
APP protein modified form binds to Heme [Hydrogen Peroxide co-treated with Sodium Nitrite] promotes the reaction [APP protein modified form binds to Heme]; Hydrogen Peroxide promotes the reaction [APP protein modified form binds to Heme] |
CTD |
PMID:25211009 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Arhgap31 |
Rho GTPase activating protein 31 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ARHGAP31 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:64,600,968...64,714,114
Ensembl chr11:64,601,029...64,714,252
|
|
G |
Asb1 |
ankyrin repeat and SOCS box-containing 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of ASB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:98,668,231...98,689,471
Ensembl chr 9:98,668,231...98,684,900
|
|
G |
Asxl2 |
ASXL transcriptional regulator 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ASXL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:27,835,346...27,919,285
Ensembl chr 6:27,887,797...27,915,563
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions |
ISO |
ATP7B gene mutant form promotes the reaction [Copper results in decreased abundance of Heme] |
CTD |
PMID:19888908 |
|
NCBI chr16:74,865,516...74,944,935
Ensembl chr16:74,865,516...74,945,286
|
|
G |
Bcar3 |
BCAR3 adaptor protein, NSP family member |
increases expression |
ISO |
Heme metabolite results in increased expression of BCAR3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:226,563,050...226,679,449
Ensembl chr 2:226,563,050...226,679,438
|
|
G |
Blvra |
biliverdin reductase A |
increases expression |
ISO |
Heme metabolite results in increased expression of BLVRA mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:119,552,550...119,577,796
Ensembl chr 3:119,561,290...119,577,806
|
|
G |
Bok |
BCL2 family apoptosis regulator BOK |
decreases expression |
ISO |
Heme metabolite results in decreased expression of BOK mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:100,829,593...100,840,498
Ensembl chr 9:100,829,552...100,840,504
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CAMK2B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:86,208,876...86,297,727
Ensembl chr14:86,208,901...86,297,652
|
|
G |
Camk2g |
calcium/calmodulin-dependent protein kinase II gamma |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CAMK2G mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:3,936,721...3,995,740
Ensembl chr15:3,936,786...3,995,915
|
|
G |
Car1 |
carbonic anhydrase 1 |
multiple interactions increases expression |
EXP |
[Heme co-treated with Calcium, Dietary] results in increased expression of CAR1 mRNA Heme results in increased expression of CAR1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:88,185,204...88,227,486
Ensembl chr 2:88,217,188...88,227,479
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of CCL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases secretion |
ISO |
Heme analog results in increased secretion of CCL3 protein |
CTD |
PMID:23355332 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccl6 |
C-C motif chemokine ligand 6 |
increases expression |
ISO |
Heme metabolite results in increased expression of CCL6 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:70,798,118...70,802,750
Ensembl chr10:70,797,124...70,802,782
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
multiple interactions |
ISO |
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein] |
CTD |
PMID:19039664 |
|
NCBI chr 1:220,075,251...220,096,319
Ensembl chr 1:220,075,247...220,096,404
|
|
G |
Cd2 |
Cd2 molecule |
increases expression |
ISO |
Heme metabolite results in increased expression of CD2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:203,666,706...203,680,073
Ensembl chr 2:203,666,637...203,680,083
|
|
G |
Cel |
carboxyl ester lipase |
decreases expression multiple interactions |
EXP |
Heme results in decreased expression of CEL mRNA [Heme co-treated with Calcium, Dietary] results in decreased expression of CEL mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 3:7,134,021...7,141,522
Ensembl chr 3:7,134,021...7,141,522
|
|
G |
Clca1 |
chloride channel accessory 1 |
decreases expression |
EXP |
Heme results in decreased expression of CLCA1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:250,897,980...250,923,711
Ensembl chr 2:250,897,969...250,923,744
|
|
G |
Cnot9 |
CCR4-NOT transcription complex subunit 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of CNOT9 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:81,783,349...81,808,815
Ensembl chr 9:81,783,349...81,808,805
|
|
G |
Cops5 |
COP9 signalosome subunit 5 |
increases expression |
ISO |
Heme metabolite results in increased expression of COPS5 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:8,876,090...8,894,345
Ensembl chr 5:8,876,044...8,894,339
|
|
G |
Cpox |
coproporphyrinogen oxidase |
increases chemical synthesis |
ISO |
CPOX protein results in increased chemical synthesis of Heme |
CTD |
PMID:11248690 |
|
NCBI chr11:44,039,665...44,049,648
Ensembl chr11:44,039,669...44,049,648
|
|
G |
Csf2 |
colony stimulating factor 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of CSF2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of CXCL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cyb5a |
cytochrome b5 type A |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr18:81,694,818...81,726,821
Ensembl chr18:81,694,808...81,726,821
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Dgcr8 |
DGCR8 microprocessor complex subunit |
affects binding |
ISO |
DGCR8 protein binds to Heme; DGCR8 protein mutant form binds to Heme |
CTD |
PMID:21454614 |
|
NCBI chr11:86,852,682...86,885,233
Ensembl chr11:86,852,711...86,885,224
|
|
G |
Dnajc7 |
DnaJ heat shock protein family (Hsp40) member C7 |
decreases expression |
EXP |
Heme results in decreased expression of DNAJC7 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr10:88,498,271...88,533,730
Ensembl chr10:88,498,238...88,533,829
|
|
G |
Dner |
delta/notch-like EGF repeat containing |
decreases expression |
ISO |
Heme metabolite results in decreased expression of DNER mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:91,965,866...92,291,172
Ensembl chr 9:91,965,866...92,291,220
|
|
G |
Dusp14 |
dual specificity phosphatase 14 |
increases expression |
ISO |
Heme metabolite results in increased expression of DUSP14 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:71,363,688...71,383,602
Ensembl chr10:71,363,688...71,383,602
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of DUSP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:119,776,925...119,779,110
Ensembl chr 3:119,776,925...119,779,099
|
|
G |
Eif2s3 |
eukaryotic translation initiation factor 2 subunit gamma |
decreases expression |
ISO |
Heme metabolite results in decreased expression of EIF2S3X mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:63,268,106...63,291,125
Ensembl chr X:63,268,037...63,292,092
|
|
G |
Eno2 |
enolase 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of ENO2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Heme metabolite results in increased expression of EREG mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:18,577,620...18,591,395
Ensembl chr14:18,576,355...18,591,394
|
|
G |
Esrra |
estrogen related receptor, alpha |
decreases expression |
ISO |
Heme metabolite results in decreased expression of ESRRA mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:222,168,729...222,178,842
Ensembl chr 1:222,168,730...222,178,725
|
|
G |
F10 |
coagulation factor X |
increases expression |
ISO |
Heme metabolite results in increased expression of F10 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:81,803,169...81,822,476
Ensembl chr16:81,803,110...81,822,716
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions increases expression |
ISO |
Curcumin inhibits the reaction [Heme results in increased expression of F3 mRNA]; Heme results in increased expression of and results in increased activity of F3 protein; Sulfasalazine inhibits the reaction [Heme results in increased expression of F3 mRNA] |
CTD |
PMID:18983524 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fabp2 |
fatty acid binding protein 2 |
increases expression multiple interactions |
EXP |
Heme results in increased expression of FABP2 mRNA [Heme co-treated with Calcium, Dietary] results in increased expression of FABP2 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 2:227,080,912...227,083,654
Ensembl chr 2:227,080,924...227,083,501
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of FABP3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:148,528,854...148,535,597
Ensembl chr 5:148,528,725...148,535,565
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
Heme metabolite results in decreased expression of FOS mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fxyd4 |
FXYD domain-containing ion transport regulator 4 |
decreases expression |
EXP |
Heme results in decreased expression of FXYD4 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr 4:149,984,206...149,988,744
Ensembl chr 4:149,984,206...149,988,295
|
|
G |
Gfod1 |
glucose-fructose oxidoreductase domain containing 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of GFOD1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:23,818,370...23,924,393
Ensembl chr17:23,823,632...23,923,792
|
|
G |
Gipc1 |
GIPC PDZ domain containing family, member 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of GIPC1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr19:24,786,604...24,798,231
Ensembl chr19:24,786,628...24,798,233
|
|
G |
Gpr176 |
G protein-coupled receptor 176 |
increases expression |
ISO |
Heme metabolite results in increased expression of GPR176 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:110,042,853...110,140,756
Ensembl chr 3:110,042,853...110,140,756
|
|
G |
Gprc5a |
G protein-coupled receptor, class C, group 5, member A |
increases expression |
ISO |
Heme metabolite results in increased expression of GPRC5A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:168,832,937...168,851,650
Ensembl chr 4:168,832,910...168,851,652
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases expression |
ISO |
Heme metabolite results in increased expression of GPT mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions |
EXP |
5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]] |
CTD |
PMID:19466990 |
|
NCBI chr 2:181,045,694...181,103,321
Ensembl chr 2:181,045,703...181,102,918
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO EXP |
Polysorbates inhibits the reaction [Heme binds to GUCY1B1 protein] 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]; zinc protoporphyrin inhibits the reaction [5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]]; zinc protoporphyrin inhibits the reaction [BAY 58-2667 inhibits the reaction [Heme deficiency results in decreased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]] |
CTD |
PMID:19466990 PMID:22171090 |
|
NCBI chr 2:180,976,939...181,026,001
Ensembl chr 2:180,976,939...181,026,024
|
|
G |
Hectd3 |
HECT domain E3 ubiquitin protein ligase 3 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of HECTD3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:135,860,578...135,870,535
Ensembl chr 5:135,860,675...135,868,495
|
|
G |
Hk3 |
hexokinase 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of HK3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:10,134,726...10,152,976
Ensembl chr17:10,137,974...10,152,956
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression multiple interactions increases degradation decreases abundance increases metabolic processing increases expression |
ISO EXP |
Heme results in decreased expression of HMOX1 mRNA [stannous chloride results in increased activity of HMOX1 protein] which results in decreased abundance of Heme; Heme promotes the reaction [Trinitrobenzenesulfonic Acid results in increased expression of and results in increased activity of HMOX1 protein] HMOX1 protein results in increased degradation of Heme HMOX1 protein results in decreased abundance of Heme HMOX1 protein results in increased metabolism of Heme [HMOX1 protein results in increased degradation of Heme] which results in increased abundance of Iron; NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA]; SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; HMOX1 enhancer affects the reaction [Heme results in increased expression of HMOX1 mRNA]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] Heme metabolite results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 mRNA Heme analog results in increased expression of HMOX1 protein; Heme results in increased expression of HMOX1 mRNA; Heme results in increased expression of HMOX1 protein |
CTD |
PMID:7538129 PMID:8630002 PMID:9224953 PMID:10874044 PMID:12783778 PMID:15242350 PMID:16959961 PMID:17156779 PMID:17292349 PMID:18178725 PMID:19039664 PMID:19136476 PMID:19191707 PMID:19952508 PMID:20638379 PMID:22859313 PMID:32671443 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hpx |
hemopexin |
multiple interactions affects binding |
ISO |
[Heme binds to HPX protein] inhibits the reaction [Triethylenephosphoramide results in increased expression of CCS protein]; [Heme binds to HPX protein] which results in increased degradation of CCS protein; [Heme binds to HPX protein] which results in increased expression of HMOX1 protein; [Heme co-treated with HPX protein] affects the activity of MT1 promoter; [Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein]; Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]; Copper inhibits the reaction [Heme binds to HPX protein]; lactacystin inhibits the reaction [[Heme binds to HPX protein] which results in increased degradation of CCS protein]; Triethylenephosphoramide inhibits the reaction [Copper deficiency inhibits the reaction [[Heme binds to HPX protein] which results in increased expression of HMOX1 protein]] |
CTD |
PMID:11213479 PMID:19039664 |
|
NCBI chr 1:170,423,558...170,431,066
Ensembl chr 1:170,423,483...170,431,073
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] |
CTD |
PMID:11076874 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Heme metabolite results in increased expression of IL1A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] Heme analog results in increased secretion of IL1B protein |
CTD |
PMID:11076874 PMID:23355332 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of IL1RL1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:47,133,483...47,184,316
Ensembl chr 9:47,134,034...47,182,170
|
|
G |
Il20 |
interleukin 20 |
increases expression |
ISO |
Heme metabolite results in increased expression of IL20 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:47,644,071...47,651,487
Ensembl chr13:47,644,071...47,647,715
|
|
G |
Il7r |
interleukin 7 receptor |
increases expression |
ISO |
Heme metabolite results in increased expression of IL7R mRNA |
CTD |
PMID:19191707 |
|
|
|
G |
Irf3 |
interferon regulatory factor 3 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of IRF3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:100,992,244...100,997,202
Ensembl chr 1:100,992,405...100,997,198
|
|
G |
Irf4 |
interferon regulatory factor 4 |
increases expression |
ISO |
Heme metabolite results in increased expression of IRF4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:34,886,746...34,905,191
Ensembl chr17:34,886,739...34,905,117
|
|
G |
Itln1 |
intelectin 1 |
decreases expression |
EXP |
Heme results in decreased expression of ITLN1 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr13:89,919,570...89,929,774
Ensembl chr13:89,919,667...89,929,770
|
|
G |
Krt20 |
keratin 20 |
increases expression |
EXP |
Heme results in increased expression of KRT20 mRNA |
CTD |
PMID:15539406 |
|
NCBI chr10:87,342,514...87,351,045
Ensembl chr10:87,342,619...87,351,045
|
|
G |
Lep |
leptin |
multiple interactions increases abundance |
ISO |
cobaltiprotoporphyrin inhibits the reaction [LEP gene mutant form results in increased abundance of Heme]; tin mesoporphyrin inhibits the reaction [cobaltiprotoporphyrin inhibits the reaction [LEP gene mutant form results in increased abundance of Heme]] |
CTD |
PMID:23839791 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
LOC100364500 |
RT1 class I, locus CE11-like |
decreases expression |
ISO |
Heme metabolite results in decreased expression of H2-Q1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:2,704,153...2,707,111
Ensembl chr20:2,704,148...2,707,120
|
|
G |
Lyz2 |
lysozyme 2 |
increases secretion multiple interactions |
ISO |
Heme analog results in increased secretion of LYZ protein SB 203580 inhibits the reaction [Heme analog results in increased secretion of LYZ protein] |
CTD |
PMID:23355332 |
|
NCBI chr 7:60,335,968...60,341,264
Ensembl chr 7:60,335,969...60,341,264
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Heme inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:17292349 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mptx1 |
mucosal pentraxin 1 |
decreases expression multiple interactions |
EXP |
Heme results in decreased expression of MPTX1 mRNA Calcium, Dietary inhibits the reaction [Heme results in decreased expression of MPTX1 mRNA] |
CTD |
PMID:15539406 |
|
NCBI chr13:91,772,927...91,827,231
Ensembl chr13:91,773,004...91,776,397
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
decreases expression |
ISO |
Heme metabolite results in decreased expression of MRE11A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:13,304,355...13,350,329
Ensembl chr 8:13,305,152...13,352,489
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions decreases response to substance |
ISO |
[Heme co-treated with HPX protein] affects the activity of MT1 promoter MT1A protein results in decreased susceptibility to Heme |
CTD |
PMID:11213479 PMID:11878821 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mtf1 |
metal-regulatory transcription factor 1 |
multiple interactions |
ISO |
[Heme co-treated with HPX protein] affects the localization of MTF1 protein; bathocuproine sulfonate inhibits the reaction [[Heme co-treated with HPX protein] affects the localization of MTF1 protein] |
CTD |
PMID:11213479 |
|
NCBI chr 5:142,797,340...142,843,896
Ensembl chr 5:142,797,366...142,842,122
|
|
G |
Mtmr10 |
myotubularin related protein 10 |
increases expression |
ISO |
Heme metabolite results in increased expression of MTMR10 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:125,124,743...125,175,857
Ensembl chr 1:125,124,743...125,175,857
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions |
ISO |
NFE2L2 mutant form inhibits the reaction [Heme results in increased expression of HMOX1 mRNA] |
CTD |
PMID:10874044 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
affects localization |
ISO |
Heme analog affects the localization of NFKB1 protein |
CTD |
PMID:23355332 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Heme analog results in increased phosphorylation of and results in increased degradation of NFKBIA protein |
CTD |
PMID:23355332 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Ngb |
neuroglobin |
affects binding |
ISO |
Carbon Dioxide binds to [Heme binds to NGB protein]; Heme binds to NGB protein |
CTD |
PMID:16684569 |
|
NCBI chr 6:111,126,259...111,131,699
Ensembl chr 6:111,126,261...111,132,320
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] |
CTD |
PMID:11076874 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Pars2 |
prolyl-tRNA synthetase 2, mitochondrial |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PARS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:126,254,090...126,259,204
Ensembl chr 5:126,254,142...126,259,200
|
|
G |
Pcsk2 |
proprotein convertase subtilisin/kexin type 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PCSK2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:137,618,891...137,923,385
Ensembl chr 3:137,618,898...137,925,605
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PDGFB mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:121,215,458...121,233,092
Ensembl chr 7:121,214,628...121,232,741
|
|
G |
Pgap2 |
post-GPI attachment to proteins 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PGAP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:167,309,021...167,335,550
Ensembl chr 1:167,309,051...167,334,741
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PHLDA1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:54,247,460...54,249,664
Ensembl chr 7:54,247,460...54,249,664
|
|
G |
Pja2 |
praja ring finger ubiquitin ligase 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of PJA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:111,998,204...112,048,847
Ensembl chr 9:111,998,203...112,027,240
|
|
G |
Plekhm1 |
pleckstrin homology and RUN domain containing M1 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLEKHM1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:91,451,890...91,500,675
Ensembl chr10:91,451,865...91,500,661
|
|
G |
Plekho1 |
pleckstrin homology domain containing O1 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLEKHO1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:198,112,104...198,120,202
Ensembl chr 2:198,112,076...198,120,120
|
|
G |
Plk2 |
polo-like kinase 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLK2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:41,911,143...41,916,901
Ensembl chr 2:41,911,131...41,916,901
|
|
G |
Plxna2 |
plexin A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PLXNA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:113,373,569...113,570,774
Ensembl chr13:113,373,578...113,571,648
|
|
G |
Pomt1 |
protein-O-mannosyltransferase 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of POMT1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:11,253,424...11,271,873
Ensembl chr 3:11,254,026...11,271,872
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
ISO |
[CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 12-hydroxyellipticine]; [CYB5A protein co-treated with Heme] promotes the reaction [[CYP3A4 protein co-treated with POR protein co-treated with NADP] results in increased chemical synthesis of 13-hydroxyellipticine] |
CTD |
PMID:22390216 |
|
NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
|
|
G |
Ppie |
peptidylprolyl isomerase E |
increases expression |
ISO |
Heme metabolite results in increased expression of PPIE mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:140,822,141...140,835,244
Ensembl chr 5:140,822,141...140,834,959
|
|
G |
Pstpip2 |
proline-serine-threonine phosphatase-interacting protein 2 |
increases expression |
ISO |
Heme metabolite results in increased expression of PSTPIP2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:74,173,809...74,291,188
Ensembl chr18:74,174,936...74,292,921
|
|
G |
Rab33a |
RAB33A, member RAS oncogene family |
increases expression |
ISO |
Heme metabolite results in increased expression of RAB33A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:135,348,799...135,360,204
Ensembl chr X:135,348,436...135,360,203
|
|
G |
Rab3a |
RAB3A, member RAS oncogene family |
decreases expression |
ISO |
Heme metabolite results in decreased expression of RAB3A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:20,435,098...20,439,206
Ensembl chr16:20,435,101...20,439,206
|
|
G |
Rbm39 |
RNA binding motif protein 39 |
increases expression |
ISO |
Heme metabolite results in increased expression of RBM39 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:151,691,498...151,724,723
Ensembl chr 3:151,691,514...151,724,654
|
|
G |
Rbx1 |
ring-box 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of RBX1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:122,700,849...122,710,907
Ensembl chr 7:122,700,854...122,709,935
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization |
ISO |
Heme analog affects the localization of RELA protein |
CTD |
PMID:23355332 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Rhebl1 |
RHEB like 1 |
increases expression |
ISO |
Heme metabolite results in increased expression of RHEBL1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:140,552,704...140,556,980
Ensembl chr 7:140,552,733...140,556,639
|
|
G |
Rpap1 |
RNA polymerase II associated protein 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of RPAP1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:111,565,646...111,587,184
Ensembl chr 3:111,565,650...111,587,151
|
|
G |
Rps6ka2 |
ribosomal protein S6 kinase A2 |
increases expression |
ISO |
Heme metabolite results in increased expression of RPS6KA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:53,219,346...53,499,445
Ensembl chr 1:53,360,157...53,499,445
|
|
G |
RT1-Bb |
RT1 class II, locus Bb |
decreases expression |
ISO |
Heme metabolite results in decreased expression of H2-AB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:4,043,726...4,049,367
Ensembl chr20:4,039,413...4,049,711
|
|
G |
RT1-S3 |
RT1 class Ib, locus S3 |
increases expression |
ISO |
Heme metabolite results in increased expression of H2-T23 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:3,176,124...3,180,825
Ensembl chr20:3,176,107...3,179,818
|
|
G |
Setdb1 |
SET domain bifurcated histone lysine methyltransferase 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SETDB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:196,495,867...196,527,412
Ensembl chr 2:196,495,867...196,527,127
|
|
G |
Slamf7 |
SLAM family member 7 |
increases expression |
ISO |
Heme metabolite results in increased expression of SLAMF7 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:90,056,726...90,075,159
Ensembl chr13:90,058,127...90,075,144
|
|
G |
Slc46a1 |
solute carrier family 46 member 1 |
multiple interactions increases uptake |
ISO |
SLC46A1 protein promotes the reaction [Heme results in increased expression of HMOX1 mRNA] SLC46A1 protein results in increased uptake of Heme |
CTD |
PMID:17156779 |
|
NCBI chr10:65,728,508...65,741,708
Ensembl chr10:65,733,991...65,740,828
|
|
G |
Smarcb1 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SMARCB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:13,679,955...13,702,821
Ensembl chr20:13,680,716...13,704,931
|
|
G |
Smc4 |
structural maintenance of chromosomes 4 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of SMC4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:165,600,934...165,629,415
Ensembl chr 2:165,601,007...165,629,415
|
|
G |
Srp9 |
signal recognition particle 9 |
increases expression |
ISO |
Heme metabolite results in increased expression of SRP9 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:100,551,307...100,559,447
Ensembl chr13:100,551,307...100,559,447
|
|
G |
Stard4 |
StAR-related lipid transfer domain containing 4 |
increases expression |
ISO |
Heme metabolite results in increased expression of STARD4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:25,982,210...25,997,555
Ensembl chr18:25,984,638...25,997,555
|
|
G |
Taf7 |
TATA-box binding protein associated factor 7 |
increases expression |
ISO |
Heme metabolite results in increased expression of TAF7 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:30,779,149...30,781,297
Ensembl chr18:30,779,150...30,781,292
|
|
G |
Tdo2 |
tryptophan 2,3-dioxygenase |
multiple interactions |
EXP |
Heme promotes the reaction [pyridine results in increased activity of TDO2 protein] |
CTD |
PMID:10413312 |
|
NCBI chr 2:180,897,059...180,914,919
Ensembl chr 2:180,897,011...180,914,940
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion |
ISO |
Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 mRNA]; Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased expression of NOS2 protein]; tin protoporphyrin IX inhibits the reaction [Heme inhibits the reaction [[IL1B protein co-treated with TNF protein co-treated with IFNG protein] results in increased activity of NOS2 protein]] Heme analog results in increased secretion of TNF protein |
CTD |
PMID:11076874 PMID:23355332 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfsf13b |
TNF superfamily member 13b |
decreases expression |
ISO |
Heme metabolite results in decreased expression of TNFSF13B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:85,275,690...85,306,419
Ensembl chr16:85,275,678...85,306,366
|
|
G |
Tollip |
toll interacting protein |
increases expression |
ISO |
Heme metabolite results in increased expression of TOLLIP mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:214,823,993...214,844,861
Ensembl chr 1:214,823,978...214,844,858
|
|
G |
Tuba4a |
tubulin, alpha 4A |
increases expression |
ISO |
Heme metabolite results in increased expression of TUBA4A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:82,415,599...82,419,918
Ensembl chr 9:82,415,605...82,419,288
|
|
G |
Ube2l3 |
ubiquitin-conjugating enzyme E2L 3 |
increases expression |
ISO |
Heme metabolite results in increased expression of UBE2L3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:88,047,186...88,088,477
Ensembl chr11:88,047,832...88,088,476
|
|
G |
Ube2r2 |
ubiquitin-conjugating enzyme E2R 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of UBE2R2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:57,472,315...57,530,973
Ensembl chr 5:57,472,315...57,530,987
|
|
G |
Wfikkn2 |
WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of WFIKKN2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:81,936,156...81,943,142
Ensembl chr10:81,936,444...81,942,188
|
|
G |
Yeats2 |
YEATS domain containing 2 |
decreases expression |
ISO |
Heme metabolite results in decreased expression of YEATS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:84,330,064...84,595,296
Ensembl chr11:84,330,064...84,583,542
|
|
|
G |
Aco1 |
aconitase 1 |
decreases activity |
EXP |
Hemin results in decreased activity of ACO1 protein |
CTD |
PMID:16568477 |
|
NCBI chr 5:56,425,076...56,481,218
Ensembl chr 5:56,425,024...56,481,218
|
|
G |
Aco2 |
aconitase 2 |
increases expression |
EXP |
Hemin results in increased expression of ACO2 protein |
CTD |
PMID:16568477 |
|
NCBI chr 7:123,102,493...123,145,608
Ensembl chr 7:123,102,468...123,145,635
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases secretion |
EXP |
Hemin results in increased secretion of ADIPOQ protein |
CTD |
PMID:20016031 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Hemin inhibits the reaction [IL18 protein results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:18215737 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of ALAS2 mRNA [catechol co-treated with Hemin] results in increased expression of ALAS2 mRNA; [S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA; [S-Adenosylmethionine co-treated with Hemin] results in increased expression of ALAS2 mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA]; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of ALAS2 mRNA]; catechol promotes the reaction [Hemin results in increased expression of ALAS2 mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of ALAS2 mRNA]; Hemin promotes the reaction [catechol results in increased expression of ALAS2 mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of ALAS2 mRNA] |
CTD |
PMID:23973255 PMID:24141029 PMID:28552822 |
|
NCBI chr X:23,167,576...23,187,356
Ensembl chr X:23,167,696...23,187,341
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Hemin binds to ALB protein |
CTD |
PMID:10506189 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
EXP |
Hemin inhibits the reaction [Nitroglycerin results in decreased activity of ALDH2 protein] |
CTD |
PMID:17541025 |
|
NCBI chr12:40,466,418...40,498,813
Ensembl chr12:40,466,495...40,498,752
|
|
G |
Arl6ip5 |
ADP-ribosylation factor like GTPase 6 interacting protein 5 |
increases expression |
ISO |
Hemin results in increased expression of ARL6IP5 protein |
CTD |
PMID:16430862 |
|
NCBI chr 4:129,574,363...129,598,240
Ensembl chr 4:129,574,264...129,598,915
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
multiple interactions |
ISO |
Hemin results in decreased localization of and results in decreased activity of BACH1 protein |
CTD |
PMID:18550526 |
|
NCBI chr11:27,364,913...27,398,713
Ensembl chr11:27,364,916...27,398,842
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
Hemin promotes the reaction [Cisplatin results in increased expression of BAX protein] Hemin results in increased expression of BAX protein |
CTD |
PMID:27815112 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Hemin results in decreased expression of BCL2 protein |
CTD |
PMID:27815112 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
increases expression |
ISO |
Hemin results in increased expression of BIRC2 protein |
CTD |
PMID:14647439 |
|
NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
EXP ISO |
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with Hemin] results in increased cleavage of CASP3 protein; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased cleavage of CASP3 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased cleavage of CASP3 protein]; Hemin inhibits the reaction [Cadmium Chloride results in increased activity of CASP3 protein]; Hemin inhibits the reaction [Carbon Monoxide results in increased cleavage of and results in increased activity of CASP3 protein]; Hemin inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein]; Hemin inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [Hemin inhibits the reaction [Carbon Monoxide results in increased cleavage of and results in increased activity of CASP3 protein]] [SESN2 protein affects the susceptibility to Hemin] which results in decreased expression of CASP3 protein modified form Hemin results in increased cleavage of CASP3 protein Hemin promotes the reaction [Cisplatin results in increased cleavage of CASP3 protein] |
CTD |
PMID:17173083 PMID:18845130 PMID:19150641 PMID:19520142 PMID:26747958 PMID:27815112 PMID:31054940 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
Hemin inhibits the reaction [Cadmium Chloride results in decreased activity of CAT protein] Hemin inhibits the reaction [Cisplatin results in decreased activity of CAT protein] |
CTD |
PMID:19150641 PMID:27815112 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
EXP |
[Hemin co-treated with indole-3-carbinol co-treated with 1,2-Dimethylhydrazine] affects the expression of CDH1 mRNA |
CTD |
PMID:29269057 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of CDKN1A protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Hemin results in increased expression of CDKN1A protein]; SB 203580 inhibits the reaction [Hemin results in increased expression of CDKN1A protein] |
CTD |
PMID:14647439 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases degradation |
ISO |
Hemin results in decreased degradation of CDKN1B protein |
CTD |
PMID:17283133 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions increases expression |
ISO |
HAMP mRNA promotes the reaction [Hemin results in increased expression of CEBPA mRNA] |
CTD |
PMID:29749404 |
|
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
|
|
G |
Chd4 |
chromodomain helicase DNA binding protein 4 |
multiple interactions |
ISO |
[Hemin co-treated with hexamethylene bisacetamide] inhibits the reaction [CHD4 protein binds to OGT protein]; [Hemin co-treated with hexamethylene bisacetamide] inhibits the reaction [thiamet G results in increased O-linked glycosylation of CHD4 protein]; [Hemin co-treated with hexamethylene bisacetamide] results in decreased O-linked glycosylation of CHD4 protein |
CTD |
PMID:27231347 |
|
NCBI chr 4:157,612,531...157,645,660
Ensembl chr 4:157,612,536...157,645,659
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of ALAS2 mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HBB mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HMBS mRNA] |
CTD |
PMID:24141029 |
|
NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
|
|
G |
Crh |
corticotropin releasing hormone |
increases secretion multiple interactions |
ISO |
Hemin results in increased secretion of CRH protein mesoporphyrin IX analog inhibits the reaction [Hemin results in increased secretion of CRH protein] |
CTD |
PMID:11232018 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NOX2 mRNA]; Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NOX2 protein]; tin protoporphyrin IX inhibits the reaction [Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NOX2 mRNA]]; tin protoporphyrin IX inhibits the reaction [Hemin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NOX2 protein]] |
CTD |
PMID:23272707 |
|
NCBI chr X:14,578,330...14,610,049
Ensembl chr X:14,578,264...14,612,547
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO EXP |
Hemin inhibits the reaction [Lead inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]; Hemin inhibits the reaction [Mercuric Chloride inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]; Hemin inhibits the reaction [sodium arsenite inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]]; Hemin promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in decreased expression of CYP1A1 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in decreased expression of CYP1A1 protein]; Hemin inhibits the reaction [arsenite inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]] |
CTD |
PMID:20188822 PMID:20837117 PMID:22120038 PMID:22159698 PMID:26747958 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with Hemin] results in decreased expression of CYP1A2 protein; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in decreased expression of CYP1A2 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in decreased expression of CYP1A2 protein]; Hemin inhibits the reaction [arsenite inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]] |
CTD |
PMID:22159698 PMID:26747958 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of CYP2A5 mRNA; Hemin results in increased expression of CYP2A5 protein [tin protoporphyrin IX co-treated with Hemin] affects the localization of CYP2A5 protein; [tin protoporphyrin IX co-treated with Hemin] results in increased expression of CYP2A5 mRNA; [zinc protoporphyrin co-treated with Hemin] results in increased expression of CYP2A5 mRNA; NFE2L2 gene mutant form inhibits the reaction [Hemin results in increased expression of CYP2A5 mRNA] |
CTD |
PMID:22859313 |
|
NCBI chr 1:83,653,248...83,662,118
Ensembl chr 1:83,653,234...83,766,484
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions |
EXP |
[[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] co-treated with Hemin] results in decreased expression of CYP2B1 protein; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in decreased expression of CYP2B1 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in decreased expression of CYP2B1 protein] |
CTD |
PMID:26747958 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions |
ISO |
Dimethyl Sulfoxide promotes the reaction [Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]; Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]; Hemin promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]] |
CTD |
PMID:11368792 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP ISO |
Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of CYP2E1 mRNA]; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of CYP2E1 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of CYP2E1 mRNA]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of CYP2E1 protein] Hemin inhibits the reaction [Ethanol results in increased expression of and results in increased activity of CYP2E1 protein] |
CTD |
PMID:19325051 PMID:26747958 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
EXP ISO |
Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of DDIT3 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of DDIT3 protein] Hemin results in increased expression of DDIT3 mRNA |
CTD |
PMID:26747958 PMID:29749404 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Efna1 |
ephrin A1 |
multiple interactions |
ISO |
[hydroquinone co-treated with Hemin] affects the expression of EFNA1 mRNA |
CTD |
PMID:32198055 |
|
NCBI chr 2:188,588,808...188,596,156
Ensembl chr 2:188,588,796...188,596,222
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased phosphorylation of EIF2AK3 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:26747958 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Hemin results in increased expression of FOS mRNA]; Dactinomycin inhibits the reaction [Hemin results in increased expression of FOS mRNA]; KN 62 inhibits the reaction [Hemin results in increased expression of FOS mRNA]; staurosporine aglycone inhibits the reaction [Hemin results in increased expression of FOS mRNA] |
CTD |
PMID:10381381 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
decreases expression |
ISO |
Hemin results in decreased expression of FOSL1 protein |
CTD |
PMID:20006635 |
|
NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression |
EXP ISO |
Hemin results in increased expression of FTH1 mRNA; Hemin results in increased expression of FTH1 protein |
CTD |
PMID:15893546 PMID:16568477 PMID:17469137 PMID:29749404 PMID:31054940 |
|
NCBI chr 1:226,030,940...226,033,228
Ensembl chr 1:226,030,938...226,033,228
|
|
G |
Ftl1 |
ferritin light chain 1 |
multiple interactions increases expression |
ISO EXP |
[Hemin results in increased abundance of Iron] which results in increased expression of FTL mRNA Hemin results in increased expression of FTL1 mRNA Hemin results in increased expression of FTL mRNA; Hemin results in increased expression of FTL1 protein |
CTD |
PMID:12393473 PMID:15893546 PMID:16568477 PMID:29749404 |
|
NCBI chr 1:101,448,190...101,450,034
Ensembl chr 1:101,448,346...101,449,829
|
|
G |
Gas1 |
growth arrest-specific 1 |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of GAS1 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr17:4,846,116...4,849,350
Ensembl chr17:4,846,789...4,847,940
|
|
G |
Gata1 |
GATA binding protein 1 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of GATA1 mRNA catechol promotes the reaction [Hemin results in increased expression of GATA1 mRNA]; Decitabine inhibits the reaction [hydroquinone inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]]; Decitabine inhibits the reaction [Phenol inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]]; Hemin promotes the reaction [catechol results in increased expression of GATA1 mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of GATA1 mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of GATA1 mRNA] |
CTD |
PMID:21414390 PMID:23973255 PMID:28552822 |
|
NCBI chr X:15,273,937...15,281,759
Ensembl chr X:15,378,789...15,382,066
|
|
G |
Gata2 |
GATA binding protein 2 |
decreases expression multiple interactions |
ISO |
Hemin results in decreased expression of GATA2 mRNA hydroquinone promotes the reaction [Hemin results in decreased expression of GATA2 mRNA]; hydroxyhydroquinone promotes the reaction [Hemin results in decreased expression of GATA2 mRNA]; Phenol promotes the reaction [Hemin results in decreased expression of GATA2 mRNA] |
CTD |
PMID:21414390 |
|
NCBI chr 4:120,129,028...120,142,490
Ensembl chr 4:120,133,713...120,142,488
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
Hemin results in increased expression of GCLC mRNA |
CTD |
PMID:16631525 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Hemin results in increased stability of and results in increased expression of GSTP1 mRNA |
CTD |
PMID:15313425 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gstz1 |
glutathione S-transferase zeta 1 |
decreases activity |
ISO |
Hemin results in decreased activity of GSTZ1 protein |
CTD |
PMID:1846734 |
|
NCBI chr 6:111,176,798...111,187,246
Ensembl chr 6:111,176,798...111,187,244
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
increases expression multiple interactions decreases response to substance |
ISO |
Hemin results in increased expression of HAMP mRNA [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of HIF1A mRNA; [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of IL6 mRNA; HAMP mRNA promotes the reaction [Hemin results in increased expression of CEBPA mRNA]; necrostatin-1 promotes the reaction [HAMP mRNA results in decreased susceptibility to Hemin] |
CTD |
PMID:29749404 |
|
NCBI chr 1:89,368,021...89,369,960
Ensembl chr 1:89,368,021...89,369,960
|
|
G |
Hbb |
hemoglobin subunit beta |
multiple interactions increases expression |
ISO |
[catechol co-treated with Hemin] results in increased expression of HBB mRNA; [S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA; [S-Adenosylmethionine co-treated with Hemin] results in increased expression of HBB mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA]; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HBB mRNA]; catechol promotes the reaction [Hemin results in increased expression of HBB mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HBB mRNA]; Decitabine inhibits the reaction [hydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]]; Decitabine inhibits the reaction [hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]]; Decitabine inhibits the reaction [Phenol inhibits the reaction [Hemin results in increased expression of HBB mRNA]]; Hemin promotes the reaction [catechol results in increased expression of HBB mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of HBB mRNA]; trichostatin A inhibits the reaction [hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HBB mRNA]] |
CTD |
PMID:21414390 PMID:23973255 PMID:24141029 PMID:28552822 PMID:30327826 |
|
NCBI chr 1:168,971,269...168,972,680
Ensembl chr 1:168,971,274...168,972,725
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases expression |
ISO |
[Hemin results in decreased abundance of Iron] which results in increased expression of HIF1A mRNA [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of HIF1A mRNA Hemin results in decreased expression of HIF1A mRNA |
CTD |
PMID:12393473 PMID:29749404 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmbs |
hydroxymethylbilane synthase |
multiple interactions increases expression |
ISO |
[catechol co-treated with Hemin] results in increased expression of HMBS mRNA; [S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA; [S-Adenosylmethionine co-treated with Hemin] results in increased expression of HMBS mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA]; catechol inhibits the reaction [[S-Adenosylmethionine co-treated with Hemin] results in increased expression of HMBS mRNA]; catechol promotes the reaction [Hemin results in increased expression of HMBS mRNA]; COMT mutant form inhibits the reaction [[catechol co-treated with Hemin] results in increased expression of HMBS mRNA]; Decitabine inhibits the reaction [hydroquinone inhibits the reaction [Hemin results in increased expression of HMBS mRNA]]; Decitabine inhibits the reaction [Phenol inhibits the reaction [Hemin results in increased expression of HMBS mRNA]]; Hemin promotes the reaction [catechol results in increased expression of HMBS mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of HMBS mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of HMBS mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of HMBS mRNA] |
CTD |
PMID:21414390 PMID:23973255 PMID:24141029 PMID:28552822 |
|
NCBI chr 8:48,667,278...48,674,673
Ensembl chr 8:48,667,275...48,674,748
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression decreases expression increases activity decreases response to substance |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; [Hemin results in increased abundance of Iron] which results in increased expression of HMOX1 mRNA; [Hemin results in increased activity of HMOX1 protein] which results in decreased chemical synthesis of Reactive Oxygen Species; [Hemin results in increased expression of HMOX1 protein] which results in decreased susceptibility to PDGFB protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Hemin results in increased expression of HMOX1 mRNA]; diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Genistein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Curcumin results in increased expression of HMOX1 mRNA]; herbimycin inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; HMOX1 protein promotes the reaction [Hemin results in decreased susceptibility to IL18 protein]; IFNG protein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; tin protoporphyrin IX inhibits the reaction [Hemin results in increased activity of HMOX1 protein] Hemin results in increased expression of HMOX1 mRNA; Hemin results in increased expression of HMOX1 protein Hemin results in decreased expression of HMOX1 protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Hemin] results in decreased expression of HMOX1 protein; [Hemin co-treated with Fructose] results in increased expression of HMOX1 protein; [Hemin co-treated with Nitroglycerin] results in increased expression of HMOX1 mRNA; [Hemin co-treated with Nitroglycerin] results in increased expression of HMOX1 protein; [Streptozocin co-treated with Hemin] results in increased activity of HMOX1 protein; [tin protoporphyrin IX co-treated with Hemin] results in increased expression of HMOX1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Hemin results in decreased expression of HMOX1 protein]; chromium mesoporphyrin inhibits the reaction [[Streptozocin co-treated with Hemin] results in increased activity of HMOX1 protein]; Hemin inhibits the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Hemin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]]; Hemin inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 protein]; Hemin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Acetaminophen results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Carbon Monoxide results in increased activity of HMOX1 protein]; Hemin promotes the reaction [Carbon Monoxide results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Cyclophosphamide results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]; Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Paraquat results in increased expression of HMOX1 mRNA]; protoporphyrin IX inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; tin protoporphyrin IX inhibits the reaction [Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of HMOX1 mRNA]]; tin protoporphyrin IX inhibits the reaction [Hemin results in decreased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [Hemin promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of HMOX1 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; [tin protoporphyrin IX co-treated with Hemin] results in increased expression of HMOX1 mRNA; [zinc protoporphyrin co-treated with Hemin] results in increased expression of HMOX1 mRNA; Acetylcysteine inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Apigenin inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; Apigenin inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Apigenin inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased activity of HMOX1 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; Hemin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein]; Hemin promotes the reaction [3-hydroxyflavone results in increased expression of HMOX1 protein]; Hemin promotes the reaction [baicalein results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Cisplatin results in increased expression of HMOX1 protein]; Hemin promotes the reaction [kaempferol results in increased expression of HMOX1 protein]; Hemin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of HMOX1 protein]; Hemin promotes the reaction [Quercetin results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA]; Quercetin inhibits the reaction [Hemin results in increased expression of HMOX1 protein] HMOX1 protein results in decreased susceptibility to Hemin |
CTD |
PMID:3343248 PMID:8764571 PMID:9337616 PMID:9722676 PMID:10349844 PMID:10473555 PMID:11232018 PMID:12051994 PMID:12393473 PMID:12690112 PMID:14563492 PMID:14647439 PMID:14871405 PMID:15316927 PMID:15589375 PMID:16109301 PMID:16462769 PMID:16631525 PMID:16647178 PMID:16839318 PMID:16959797 PMID:17173083 PMID:17204476 PMID:17275847 PMID:17420286 PMID:17464175 PMID:17541025 PMID:17979934 PMID:18206168 PMID:18215737 PMID:18357586 PMID:18550526 PMID:18845130 PMID:19080378 PMID:19136476 PMID:19190261 PMID:19520142 PMID:20016031 PMID:20638379 PMID:20961405 PMID:21525764 PMID:22859313 PMID:23272707 PMID:23942037 PMID:24095726 PMID:25268984 PMID:25449124 PMID:25824035 PMID:26747958 PMID:27777014 PMID:27815112 PMID:27830717 PMID:29086419 PMID:29749404 PMID:30040983 PMID:31054940 PMID:32671443 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hmox2 |
heme oxygenase 2 |
decreases response to substance |
ISO |
HMOX2 protein results in decreased susceptibility to Hemin |
CTD |
PMID:15589375 PMID:16459095 |
|
NCBI chr10:10,990,034...11,035,493
Ensembl chr10:10,990,034...11,035,484
|
|
G |
Hspa1l |
heat shock protein family A (Hsp70) member 1 like |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of HSPA1L mRNA |
CTD |
PMID:12393473 |
|
NCBI chr20:4,879,998...4,965,191
Ensembl chr20:4,959,294...4,964,963
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of HSPA9 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr18:27,731,072...27,749,235
Ensembl chr18:27,731,072...27,749,235
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of HSPH1 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr12:6,322,685...6,341,898
Ensembl chr12:6,322,668...6,341,902
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
IFNG protein inhibits the reaction [Hemin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:10349844 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il18 |
interleukin 18 |
multiple interactions decreases response to substance |
ISO |
Hemin inhibits the reaction [IL18 protein results in decreased expression of MAPK11 protein]; Hemin inhibits the reaction [IL18 protein results in decreased phosphorylation of AKT1 protein]; Hemin inhibits the reaction [IL18 protein results in increased expression of MAPK14 protein]; Hemin inhibits the reaction [IL18 protein results in increased expression of PTEN protein]; HMOX1 protein promotes the reaction [Hemin results in decreased susceptibility to IL18 protein]; zinc protoporphyrin inhibits the reaction [Hemin results in decreased susceptibility to IL18 protein] |
CTD |
PMID:18215737 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of IL6 mRNA [HAMP mRNA results in decreased susceptibility to Hemin] which results in decreased expression of IL6 mRNA |
CTD |
PMID:29749404 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
EXP |
Hemin inhibits the reaction [Fructose results in increased expression of INS protein] |
CTD |
PMID:25268984 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Ireb2 |
iron responsive element binding protein 2 |
multiple interactions |
EXP |
Hemin results in decreased expression of and results in decreased activity of IREB2 protein |
CTD |
PMID:16568477 |
|
NCBI chr 8:59,450,974...59,503,634
Ensembl chr 8:59,420,123...59,501,118
|
|
G |
Ivl |
involucrin |
decreases expression |
ISO |
Hemin results in decreased expression of IVL mRNA |
CTD |
PMID:20006635 |
|
NCBI chr 2:192,761,171...192,773,346
Ensembl chr 2:192,761,538...192,763,577
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression |
ISO EXP |
[Hemin results in decreased abundance of Iron] which results in increased expression of JUN mRNA Hemin results in decreased expression of JUN mRNA Hemin promotes the reaction [Paraquat results in increased phosphorylation of JUN protein] |
CTD |
PMID:12393473 PMID:19080378 PMID:20016031 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
decreases expression |
ISO |
Hemin results in decreased expression of KEAP1 protein |
CTD |
PMID:27777014 |
|
NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
|
|
G |
Lox |
lysyl oxidase |
multiple interactions |
ISO |
[Hemin results in decreased abundance of Iron] which results in increased expression of LOX mRNA |
CTD |
PMID:12393473 |
|
NCBI chr18:47,500,320...47,577,819
Ensembl chr18:47,500,330...47,577,819
|
|
G |
Magi1 |
membrane associated guanylate kinase, WW and PDZ domain containing 1 |
multiple interactions |
ISO |
[Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 protein; [hydroquinone co-treated with Hemin] affects the expression of MAGI1 mRNA; [hydroquinone co-treated with Hemin] affects the expression of MAGI1 protein; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 protein] |
CTD |
PMID:32198055 |
|
NCBI chr 4:125,684,816...126,300,013
Ensembl chr 4:125,687,307...125,958,112
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Hemin results in increased phosphorylation of MAPK1 protein diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16959797 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk11 |
mitogen-activated protein kinase 11 |
multiple interactions |
ISO |
Hemin inhibits the reaction [IL18 protein results in decreased expression of MAPK11 protein] |
CTD |
PMID:18215737 |
|
NCBI chr 7:130,121,678...130,129,199
Ensembl chr 7:130,121,687...130,128,604
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
Hemin inhibits the reaction [IL18 protein results in increased expression of MAPK14 protein] |
CTD |
PMID:18215737 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
diacetyldichlorofluorescein inhibits the reaction [Hemin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16959797 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Hemin promotes the reaction [Paraquat results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:19080378 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions decreases expression |
EXP |
chromium mesoporphyrin inhibits the reaction [Hemin inhibits the reaction [Streptozocin results in increased expression of MAPK9 mRNA]]; Hemin inhibits the reaction [Streptozocin results in increased expression of MAPK9 mRNA] Hemin results in decreased expression of MAPK9 mRNA |
CTD |
PMID:19190261 PMID:20016031 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Mfn1 |
mitofusin 1 |
multiple interactions |
EXP |
Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]; Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]; Hemin inhibits the reaction [zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]]; Hemin inhibits the reaction [zinc protoporphyrin promotes the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]]; zinc protoporphyrin inhibits the reaction [Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 mRNA]]; zinc protoporphyrin inhibits the reaction [Hemin inhibits the reaction [Lipopolysaccharides results in decreased expression of MFN1 protein]] |
CTD |
PMID:27830717 |
|
NCBI chr 2:118,929,738...118,971,689
Ensembl chr 2:118,929,738...118,973,698
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
multiple interactions |
EXP |
Hemin inhibits the reaction [Gallic Acid results in increased activity of MGST1 protein] |
CTD |
PMID:19111564 |
|
NCBI chr 4:172,119,382...172,134,609
Ensembl chr 4:172,119,331...172,134,607
|
|
G |
Mir486 |
microRNA 486 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of MIR486-1 mRNA [Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of MAGI1 protein; [Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 protein; hydroquinone affects the reaction [[Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of MIR486-1 mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein] |
CTD |
PMID:32198055 |
|
Ensembl chr16:73,680,363...73,680,490
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases expression |
ISO |
Hemin results in increased expression of MMP1 protein |
CTD |
PMID:19136476 |
|
NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Hemin inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein] |
CTD |
PMID:17979934 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
ISO |
[Hemin results in decreased abundance of Iron] which results in increased expression of MT2A mRNA |
CTD |
PMID:12393473 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[Hemin results in increased abundance of Iron] which results in increased expression of MYC mRNA |
CTD |
PMID:12393473 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Nfe2 |
nuclear factor, erythroid 2 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of NFE2 mRNA catechol promotes the reaction [Hemin results in increased expression of NFE2 mRNA]; Hemin promotes the reaction [catechol results in increased expression of NFE2 mRNA]; hydroquinone inhibits the reaction [Hemin results in increased expression of NFE2 mRNA]; hydroxyhydroquinone inhibits the reaction [Hemin results in increased expression of NFE2 mRNA]; Phenol inhibits the reaction [Hemin results in increased expression of NFE2 mRNA] |
CTD |
PMID:21414390 PMID:28552822 |
|
NCBI chr 7:144,872,739...144,880,092
Ensembl chr 7:144,872,747...144,880,092
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions increases expression affects localization decreases expression |
ISO EXP |
[Antineoplastic Agents binds to and results in decreased activity of NFE2L2 protein] inhibits the reaction [Hemin results in increased expression of SESN2 protein]; diacetyldichlorofluorescein inhibits the reaction [Hemin affects the localization of NFE2L2 protein]; Hemin promotes the reaction [NFE2L2 protein binds to NQO1 promoter]; SESN2 protein inhibits the reaction [Hemin results in increased expression of NFE2L2 protein] [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Hemin] affects the localization of NFE2L2 protein; Hemin promotes the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NFE2L2 protein]; tin protoporphyrin IX inhibits the reaction [Hemin results in decreased expression of NFE2L2 protein]; tin protoporphyrin IX inhibits the reaction [Hemin results in increased expression of NFE2L2 protein]; zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of NFE2L2 protein] NFE2L2 gene mutant form inhibits the reaction [Hemin results in increased expression of CYP2A5 mRNA]; NFE2L2 protein affects the reaction [Hemin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:10473555 PMID:16959797 PMID:21464371 PMID:21525764 PMID:22859313 PMID:23272707 PMID:25824035 PMID:26747958 PMID:27777014 PMID:31054940 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Hemin inhibits the reaction [Cisplatin results in increased expression of NOS2 protein]; Hemin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Hemin promotes the reaction [3-hydroxyflavone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Hemin promotes the reaction [baicalein inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Hemin promotes the reaction [hesperetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]]; Hemin promotes the reaction [kaempferol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Hemin promotes the reaction [naringenin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]]; Hemin promotes the reaction [Quercetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of NOS2 mRNA]; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of NOS2 protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of NOS2 mRNA]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of NOS2 protein] |
CTD |
PMID:14563492 PMID:15316927 PMID:26747958 PMID:27815112 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
EXP |
[Nitroglycerin co-treated with Hemin] results in increased expression of NOS3 mRNA |
CTD |
PMID:17541025 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
ISO |
Hemin results in increased expression of NQO1 mRNA; Hemin results in increased expression of NQO1 protein Hemin promotes the reaction [NFE2L2 protein binds to NQO1 promoter]; SESN2 protein inhibits the reaction [Hemin results in increased expression of NQO1 protein] |
CTD |
PMID:21464371 PMID:31054940 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
multiple interactions |
EXP |
Hemin inhibits the reaction [manganese chloride affects the expression of NRF1 protein] |
CTD |
PMID:30040983 |
|
NCBI chr 4:57,335,732...57,445,317
Ensembl chr 4:57,378,069...57,445,341
|
|
G |
Ogt |
O-linked N-acetylglucosamine (GlcNAc) transferase |
multiple interactions |
ISO |
[Hemin co-treated with hexamethylene bisacetamide] inhibits the reaction [CHD4 protein binds to OGT protein] |
CTD |
PMID:27231347 |
|
NCBI chr X:71,540,870...71,585,906
Ensembl chr X:71,528,988...71,585,908
|
|
G |
Pde5a |
phosphodiesterase 5A |
decreases expression |
EXP |
Hemin results in decreased expression of PDE5A protein |
CTD |
PMID:16839318 |
|
NCBI chr 2:226,899,604...227,044,916
Ensembl chr 2:226,900,619...227,041,576
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
[Hemin results in increased expression of HMOX1 protein] which results in decreased susceptibility to PDGFB protein |
CTD |
PMID:20961405 |
|
NCBI chr 7:121,215,458...121,233,092
Ensembl chr 7:121,214,628...121,232,741
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
multiple interactions |
ISO |
[hydroquinone co-treated with Hemin] affects the expression of PDGFRB mRNA |
CTD |
PMID:32198055 |
|
NCBI chr18:56,364,586...56,406,381
Ensembl chr18:56,364,620...56,406,381
|
|
G |
Pmp22 |
peripheral myelin protein 22 |
multiple interactions |
ISO |
[Hemin results in decreased abundance of Iron] which results in increased expression of PMP22 mRNA |
CTD |
PMID:12393473 |
|
NCBI chr10:49,538,588...49,568,583
Ensembl chr10:49,538,588...49,568,583
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions decreases activity |
ISO |
Dimethyl Sulfoxide promotes the reaction [Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]; Dimethyl Sulfoxide promotes the reaction [Hemin results in decreased activity of POR protein]; Hemin inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]; Hemin promotes the reaction [Dimethyl Sulfoxide inhibits the reaction [POR protein results in decreased expression of CYP2D6 protein]]; Hemin promotes the reaction [Dimethyl Sulfoxide results in decreased activity of POR protein] |
CTD |
PMID:11368792 |
|
NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
EXP |
Hemin inhibits the reaction [manganese chloride affects the expression of PPARGC1A protein] |
CTD |
PMID:30040983 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
Hemin inhibits the reaction [IL18 protein results in increased expression of PTEN protein] |
CTD |
PMID:18215737 |
|
NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
|
|
G |
Ptger2 |
prostaglandin E receptor 2 |
increases response to substance |
ISO |
PTGER2 gene mutant form results in increased susceptibility to Hemin |
CTD |
PMID:25451967 |
|
NCBI chr15:19,336,029...19,349,759
Ensembl chr15:19,338,175...19,350,210
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
multiple interactions |
ISO |
[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA; [hydroquinone co-treated with Hemin] affects the expression of RAP1A protein; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAP1A protein] |
CTD |
PMID:32198055 |
|
NCBI chr 2:208,193,950...208,215,186
Ensembl chr 2:208,193,954...208,215,187
|
|
G |
Rapgef2 |
Rap guanine nucleotide exchange factor 2 |
multiple interactions |
ISO |
[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA; [hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 mRNA]; MIR486-1 mRNA affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RAPGEF2 protein] |
CTD |
PMID:32198055 |
|
NCBI chr 2:177,836,191...178,057,378
Ensembl chr 2:177,836,202...178,057,157
|
|
G |
Rassf5 |
Ras association domain family member 5 |
multiple interactions |
ISO |
[Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA; [Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 protein; [hydroquinone co-treated with Hemin] affects the expression of RASSF5 mRNA; [hydroquinone co-treated with Hemin] affects the expression of RASSF5 protein; hydroquinone affects the reaction [[Hemin co-treated with MIR486-1 mRNA] affects the expression of RASSF5 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 mRNA]; MAGI1 protein affects the reaction [[hydroquinone co-treated with Hemin] affects the expression of RASSF5 protein] |
CTD |
PMID:32198055 |
|
NCBI chr13:47,956,754...48,022,333
Ensembl chr13:47,956,790...48,022,333
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases expression |
EXP |
chromium mesoporphyrin inhibits the reaction [Hemin inhibits the reaction [Streptozocin results in increased expression of RELA mRNA]]; Hemin inhibits the reaction [Streptozocin results in increased expression of RELA mRNA] Hemin results in decreased expression of RELA mRNA |
CTD |
PMID:19190261 PMID:20016031 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions increases expression affects response to substance |
ISO |
[SESN2 protein affects the susceptibility to Hemin] which results in decreased expression of CASP3 protein modified form [Antineoplastic Agents binds to and results in decreased activity of NFE2L2 protein] inhibits the reaction [Hemin results in increased expression of SESN2 protein]; Acetylcysteine inhibits the reaction [Hemin results in increased expression of SESN2 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of NFE2L2 protein]; SESN2 protein inhibits the reaction [Hemin results in increased expression of NQO1 protein] |
CTD |
PMID:31054940 |
|
NCBI chr 5:150,684,891...150,703,846
Ensembl chr 5:150,684,133...150,704,117
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
EXP |
chromium mesoporphyrin inhibits the reaction [Hemin inhibits the reaction [Streptozocin results in decreased expression of SLC2A4 protein]]; Hemin inhibits the reaction [Streptozocin results in decreased expression of SLC2A4 protein] |
CTD |
PMID:19190261 |
|
NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
Hemin promotes the reaction [Acetaminophen results in increased expression of SOD2 protein] |
CTD |
PMID:12051994 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Tfap2c |
transcription factor AP-2 gamma |
decreases expression |
EXP |
Hemin results in decreased expression of TFAP2C mRNA |
CTD |
PMID:20016031 |
|
NCBI chr 3:170,550,314...170,558,197
Ensembl chr 3:170,550,314...170,558,194
|
|
G |
Tfrc |
transferrin receptor |
decreases expression multiple interactions |
EXP ISO |
Hemin results in decreased expression of TFRC protein Hemin results in decreased expression of TFRC mRNA; Hemin results in decreased expression of TFRC protein [Hemin results in decreased abundance of Iron] which results in increased expression of TFRC mRNA; hydroquinone promotes the reaction [Hemin results in decreased expression of TFRC mRNA]; hydroxyhydroquinone promotes the reaction [Hemin results in decreased expression of TFRC mRNA]; Phenol promotes the reaction [Hemin results in decreased expression of TFRC mRNA] |
CTD |
PMID:12393473 PMID:16568477 PMID:16760464 PMID:21414390 PMID:25576684 |
|
NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
|
|
G |
Tgm2 |
transglutaminase 2 |
multiple interactions |
ISO |
[Hemin co-treated with Tretinoin] affects the localization of TGM2 protein |
CTD |
PMID:15556610 |
|
NCBI chr 3:154,597,165...154,627,257
Ensembl chr 3:154,597,168...154,627,257
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
[Hemin co-treated with indole-3-carbinol co-treated with 1,2-Dimethylhydrazine] affects the expression of TNF mRNA; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of TNF mRNA]; Hemin inhibits the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased expression of TNF protein]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of TNF mRNA]; Hemin inhibits the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased expression of TNF protein]; Hemin inhibits the reaction [Cadmium Chloride results in increased expression of TNF]; Hemin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein] Hemin inhibits the reaction [Cisplatin results in increased expression of TNF protein] |
CTD |
PMID:17173083 PMID:19150641 PMID:26747958 PMID:27815112 PMID:29269057 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
multiple interactions |
EXP |
Hemin inhibits the reaction [Nitroglycerin results in decreased phosphorylation of VASP protein] |
CTD |
PMID:17541025 |
|
NCBI chr 1:80,170,608...80,185,882
Ensembl chr 1:80,170,619...80,185,882
|
|
G |
Zfp36 |
zinc finger protein 36 |
multiple interactions increases expression |
ISO |
zinc protoporphyrin inhibits the reaction [Hemin results in increased expression of ZFP36 mRNA] |
CTD |
PMID:24095726 |
|
NCBI chr 1:85,380,088...85,382,565
Ensembl chr 1:85,380,088...85,382,569
|
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions |
ISO |
Hydroxocobalamin results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein] |
CTD |
PMID:22171090 |
|
NCBI chr 2:181,045,694...181,103,321
Ensembl chr 2:181,045,703...181,102,918
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO |
Hydroxocobalamin results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein] |
CTD |
PMID:22171090 |
|
NCBI chr 2:180,976,939...181,026,001
Ensembl chr 2:180,976,939...181,026,024
|
|
G |
Mmachc |
metabolism of cobalamin associated C |
affects binding |
ISO |
Hydroxocobalamin binds to MMACHC protein |
CTD |
PMID:19700356 |
|
NCBI chr 5:135,555,587...135,561,723
Ensembl chr 5:135,555,565...135,561,914
|
|
G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
multiple interactions |
ISO |
[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form; Aluminum inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Arsenic inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Glutathione inhibits the reaction [Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]]; Glutathione inhibits the reaction [Thimerosal inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]]; Glutathione promotes the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Lead inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; mecobalamin inhibits the reaction [Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]]; Mercury inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Thimerosal inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form] |
CTD |
PMID:26989453 |
|
NCBI chr17:66,210,444...66,295,014
Ensembl chr17:66,210,461...66,295,014
|
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
tetra(4-N-methylpyridyl)porphine binds to and affects the folding of MYC gene |
CTD |
PMID:15740131 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
ISO |
mesoporphyrin IX analog inhibits the reaction [Hemin results in increased secretion of CRH protein] |
CTD |
PMID:11232018 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[mesoporphyrin IX binds to HPX protein] which results in increased expression of HMOX1 mRNA; hexamethylene bisacetamide inhibits the reaction [[mesoporphyrin IX binds to HPX protein] which results in increased expression of HMOX1 mRNA] |
CTD |
PMID:12042074 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hpx |
hemopexin |
multiple interactions |
ISO |
[mesoporphyrin IX binds to HPX protein] which results in increased expression of HMOX1 mRNA; [mesoporphyrin IX binds to HPX protein] which results in increased expression of MT1 mRNA; [mesoporphyrin IX binds to HPX protein] which results in increased expression of MT2 mRNA; hexamethylene bisacetamide inhibits the reaction [[mesoporphyrin IX binds to HPX protein] which results in increased expression of HMOX1 mRNA]; hexamethylene bisacetamide promotes the reaction [[mesoporphyrin IX binds to HPX protein] which results in increased expression of MT1 mRNA]; hexamethylene bisacetamide promotes the reaction [[mesoporphyrin IX binds to HPX protein] which results in increased expression of MT2 mRNA] |
CTD |
PMID:12042074 |
|
NCBI chr 1:170,423,558...170,431,066
Ensembl chr 1:170,423,483...170,431,073
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions |
ISO |
[mesoporphyrin IX binds to HPX protein] which results in increased expression of MT1 mRNA; hexamethylene bisacetamide promotes the reaction [[mesoporphyrin IX binds to HPX protein] which results in increased expression of MT1 mRNA] |
CTD |
PMID:12042074 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
ISO |
[mesoporphyrin IX binds to HPX protein] which results in increased expression of MT2 mRNA; hexamethylene bisacetamide promotes the reaction [[mesoporphyrin IX binds to HPX protein] which results in increased expression of MT2 mRNA] |
CTD |
PMID:12042074 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
mecobalamin inhibits the reaction [Homocysteine results in increased activity of CASP3 protein] |
CTD |
PMID:21237187 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
mecobalamin inhibits the reaction [Homocysteine results in increased activity of CASP7 protein] |
CTD |
PMID:21237187 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
multiple interactions increases activity |
ISO |
Aluminum inhibits the reaction [mecobalamin results in increased activity of MTR protein alternative form]; Arsenic inhibits the reaction [mecobalamin results in increased activity of MTR protein alternative form]; Buthionine Sulfoximine inhibits the reaction [mecobalamin results in increased activity of MTR protein alternative form]; Lead inhibits the reaction [mecobalamin results in increased activity of MTR protein alternative form]; mecobalamin inhibits the reaction [Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]]; Mercury inhibits the reaction [mecobalamin results in increased activity of MTR protein alternative form]; Thimerosal inhibits the reaction [mecobalamin results in increased activity of MTR protein alternative form] |
CTD |
PMID:26989453 |
|
NCBI chr17:66,210,444...66,295,014
Ensembl chr17:66,210,461...66,295,014
|
|
|
G |
Agl |
amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of AGL mRNA motexafin gadolinium results in decreased expression of AGL mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:219,788,234...219,843,189
Ensembl chr 2:219,788,234...219,842,986
|
|
G |
Aldh5a1 |
aldehyde dehydrogenase 5 family, member A1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of ALDH5A1 mRNA] motexafin gadolinium results in increased expression of ALDH5A1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr17:42,133,076...42,159,413
Ensembl chr17:42,133,076...42,159,413
|
|
G |
Aldh6a1 |
aldehyde dehydrogenase 6 family, member A1 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of ALDH6A1 mRNA Zinc Acetate inhibits the reaction [motexafin gadolinium results in decreased expression of ALDH6A1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 6:108,146,552...108,167,185
Ensembl chr 6:108,146,582...108,167,185
|
|
G |
Arhgap17 |
Rho GTPase activating protein 17 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of ARHGAP17 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of ARHGAP17 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:193,239,036...193,328,425
Ensembl chr 1:193,239,040...193,328,371
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of ATF3 mRNA] motexafin gadolinium results in increased expression of ATF3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of ATM mRNA] motexafin gadolinium results in increased expression of ATM mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
|
|
G |
Atr |
ATR serine/threonine kinase |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of ATR mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of ATR mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:103,673,578...103,770,886
Ensembl chr 8:103,673,411...103,770,947
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of BACH1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of BACH1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:27,364,913...27,398,713
Ensembl chr11:27,364,916...27,398,842
|
|
G |
Bag3 |
BAG cochaperone 3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of BAG3 mRNA] motexafin gadolinium results in increased expression of BAG3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:199,941,258...199,965,191
Ensembl chr 1:199,941,161...199,965,191
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of BBC3 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of BBC3 protein] |
CTD |
PMID:20530418 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of BIRC5 mRNA] motexafin gadolinium results in increased expression of BIRC5 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Bmt2 |
base methyltransferase of 25S rRNA 2 homolog |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of BMT2 mRNA motexafin gadolinium results in increased expression of BMT2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:40,064,131...40,136,074
Ensembl chr 4:40,063,932...40,136,061
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of BNIP3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of BNIP3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of BNIP3L mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of BNIP3L mRNA |
CTD |
PMID:16357179 |
|
NCBI chr15:43,643,897...43,667,123
Ensembl chr15:43,643,897...43,667,029
|
|
G |
Canx |
calnexin |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CANX mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of CANX mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:35,800,942...35,833,939
Ensembl chr10:35,800,942...35,833,861
|
|
G |
Casp3 |
caspase 3 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CASP3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CASP3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cbfb |
core-binding factor subunit beta |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CBFB mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of CBFB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:37,127,508...37,171,075
Ensembl chr19:37,127,508...37,171,069
|
|
G |
Ccnj |
cyclin J |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CCNJ mRNA motexafin gadolinium results in decreased expression of CCNJ mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:259,926,537...259,944,275
Ensembl chr 1:260,093,641...260,111,254 Ensembl chr 1:260,093,641...260,111,254
|
|
G |
Cdc16 |
cell division cycle 16 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CDC16 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDC16 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:81,493,355...81,516,493
Ensembl chr16:81,493,355...81,516,493
|
|
G |
Cdc25c |
cell division cycle 25C |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CDC25C mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CDC25C mRNA |
CTD |
PMID:16357179 |
|
NCBI chr18:27,528,768...27,550,316
Ensembl chr18:27,528,354...27,550,224
|
|
G |
Cdc27 |
cell division cycle 27 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CDC27 mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of CDC27 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:92,551,754...92,602,214
Ensembl chr10:92,554,081...92,602,082
|
|
G |
Cdc5l |
cell division cycle 5-like |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CDC5L mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDC5L mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:17,949,764...17,988,514
Ensembl chr 9:17,949,764...17,988,509
|
|
G |
Cdca2 |
cell division cycle associated 2 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CDCA2 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDCA2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr15:44,365,396...44,411,601
Ensembl chr15:44,365,405...44,411,004
|
|
G |
Cdk19 |
cyclin-dependent kinase 19 |
increases expression |
ISO |
motexafin gadolinium results in increased expression of CDK19 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr20:45,458,499...45,598,799
Ensembl chr20:45,458,558...45,598,798
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of CDK2 mRNA] motexafin gadolinium results in increased expression of CDK2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDKN1A mRNA; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDKN1A mRNA] |
CTD |
PMID:20530418 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CDKN1B mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CDKN1B mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cth |
cystathionine gamma-lyase |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CTH mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CTH mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:264,266,959...264,293,040
Ensembl chr 2:264,266,984...264,293,046
|
|
G |
Cul3 |
cullin 3 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CUL3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CUL3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:86,044,485...86,129,066
Ensembl chr 9:86,044,485...86,129,329
|
|
G |
Cyb5r1 |
cytochrome b5 reductase 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CYB5R1 mRNA motexafin gadolinium results in increased expression of CYB5R1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr13:51,229,697...51,236,447
Ensembl chr13:51,229,890...51,236,463
|
|
G |
Dapk3 |
death-associated protein kinase 3 |
multiple interactions decreases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of DAPK3 mRNA] motexafin gadolinium results in decreased expression of DAPK3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:11,392,436...11,400,855
Ensembl chr 7:11,392,437...11,400,805
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of DDIT3 mRNA] motexafin gadolinium results in increased expression of DDIT3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of DDIT4 mRNA motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of DDIT4 mRNA]; Zinc Acetate promotes the reaction [motexafin gadolinium results in increased expression of DDIT4 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
|
|
G |
Dedd2 |
death effector domain containing 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of DEDD2 mRNA] motexafin gadolinium results in increased expression of DEDD2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:82,073,024...82,089,028
Ensembl chr 1:82,072,544...82,088,275
|
|
G |
Dffb |
DNA fragmentation factor subunit beta |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of DFFB mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of DFFB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:171,250,559...171,261,875
Ensembl chr 5:171,249,633...171,262,119
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of DHCR7 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:217,018,916...217,034,890
Ensembl chr 1:217,018,916...217,034,904
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in decreased expression of DNAJB1 mRNA] motexafin gadolinium results in increased expression of DNAJB1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:24,747,178...24,750,919
Ensembl chr19:24,747,178...24,750,919
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of DNAJB4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of DNAJB4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:257,394,692...257,425,344
Ensembl chr 2:257,394,818...257,425,242
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of DNAJB6 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of DNAJB6 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:2,711,329...2,774,969
Ensembl chr 4:2,711,385...2,774,890
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of DNAJC3 mRNA] motexafin gadolinium results in increased expression of DNAJC3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr15:104,186,918...104,226,236
Ensembl chr15:104,186,792...104,226,329
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of E2F1 mRNA motexafin gadolinium results in increased expression of E2F1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
|
|
G |
E2f3 |
E2F transcription factor 3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of E2F3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of E2F3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr17:36,334,136...36,408,831
Ensembl chr17:36,334,147...36,408,831
|
|
G |
Egln1 |
egl-9 family hypoxia-inducible factor 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of EGLN1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of EGLN1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:57,660,194...57,701,158
Ensembl chr19:57,662,278...57,699,113
|
|
G |
Elp1 |
elongator acetyltransferase complex subunit 1 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of ELP1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of ELP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:73,503,406...73,552,798
Ensembl chr 5:73,503,407...73,552,798
|
|
G |
Eno1 |
enolase 1 |
increases expression |
ISO |
motexafin gadolinium results in increased expression of ENO1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:167,288,223...167,299,610
Ensembl chr 5:167,288,223...167,299,609
|
|
G |
Fadd |
Fas associated via death domain |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of FADD mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of FADD mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:217,746,176...217,748,581
Ensembl chr 1:217,742,929...217,748,628
|
|
G |
Faim |
Fas apoptotic inhibitory molecule |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of FAIM mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of FAIM mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:107,225,119...107,247,228
Ensembl chr 8:107,225,212...107,241,224 Ensembl chr 8:107,225,212...107,241,224
|
|
G |
Fam162a |
family with sequence similarity 162, member A |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of FAM162A mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of FAM162A mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:67,618,683...67,646,253
Ensembl chr11:67,618,625...67,646,253
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of FASN mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Foxo3 |
forkhead box O3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of FOXO3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of FOXO3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of GCLM mRNA motexafin gadolinium results in increased expression of GCLM mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gls |
glutaminase |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of GLS mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of GLS mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:54,212,622...54,284,879
Ensembl chr 9:54,212,767...54,284,872
|
|
G |
Gpr146 |
G protein-coupled receptor 146 |
increases expression |
ISO |
motexafin gadolinium results in increased expression of GPR146 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr12:17,343,396...17,358,631
Ensembl chr12:17,345,510...17,358,617
|
|
G |
Gpt2 |
glutamic--pyruvic transaminase 2 |
increases expression |
ISO |
motexafin gadolinium results in increased expression of GPT2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:22,599,003...22,633,529
Ensembl chr19:22,590,881...22,632,071
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of GPX1 mRNA; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of GPX1 mRNA] |
CTD |
PMID:20530418 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of GSR mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of GSR mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gtf3c2 |
general transcription factor IIIC subunit 2 |
increases expression |
ISO |
motexafin gadolinium results in increased expression of GTF3C2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:26,560,601...26,584,533
Ensembl chr 6:26,560,601...26,584,535
|
|
G |
Hbp1 |
HMG-box transcription factor 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HBP1 mRNA motexafin gadolinium results in increased expression of HBP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:51,231,479...51,257,699
Ensembl chr 6:51,231,480...51,257,625
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression |
ISO |
[motexafin gadolinium co-treated with Zinc Acetate] results in increased expression of HIF1A protein motexafin gadolinium results in increased expression of HIF1A protein |
CTD |
PMID:16357179 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hilpda |
hypoxia inducible lipid droplet-associated |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of HILPDA mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HILPDA mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:56,547,600...56,550,584
Ensembl chr 4:56,549,739...56,549,993
|
|
G |
Hipk1 |
homeodomain interacting protein kinase 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of HIPK1 mRNA] motexafin gadolinium results in increased expression of HIPK1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:206,224,015...206,274,910
Ensembl chr 2:206,224,015...206,274,079
|
|
G |
Hltf |
helicase-like transcription factor |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of HLTF mRNA motexafin gadolinium results in decreased expression of HLTF mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:104,854,571...104,914,338
Ensembl chr 2:104,854,572...104,914,173
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
[motexafin gadolinium co-treated with Zinc Acetate] results in increased expression of HMOX1 protein; motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HMOX1 mRNA] motexafin gadolinium results in increased expression of HMOX1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hrk |
harakiri, BCL2 interacting protein |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HRK mRNA motexafin gadolinium results in increased expression of HRK mRNA |
CTD |
PMID:16357179 |
|
NCBI chr12:44,008,879...44,029,211
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HSP90AB1 mRNA motexafin gadolinium results in increased expression of HSP90AB1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:17,817,791...17,823,163
Ensembl chr 9:17,817,721...17,823,243
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HSPA1A mRNA]; Zinc Acetate promotes the reaction [motexafin gadolinium results in increased expression of HSPA1A mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HSPA1B mRNA]; Zinc Acetate promotes the reaction [motexafin gadolinium results in increased expression of HSPA1B mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr20:4,877,638...4,880,112
Ensembl chr20:2,699,712...2,701,815
|
|
G |
Hspa4 |
heat shock protein family A (Hsp70) member 4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of HSPA4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HSPA4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:38,601,624...38,642,397
Ensembl chr10:38,601,624...38,642,397
|
|
G |
Hspa4l |
heat shock protein family A (Hsp70) member 4 like |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of HSPA4L mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HSPA4L mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:127,625,737...127,682,864
Ensembl chr 2:127,625,683...127,677,503
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of HSPB1 mRNA] motexafin gadolinium results in increased expression of HSPB1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HSPD1 mRNA] motexafin gadolinium results in increased expression of HSPD1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:61,680,529...61,691,202
Ensembl chr 9:61,680,530...61,690,956
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of HSPH1 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of HSPH1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr12:6,322,685...6,341,898
Ensembl chr12:6,322,668...6,341,902
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of ID2 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of ID2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:44,360,077...44,361,908
Ensembl chr 6:44,348,501...44,363,915
|
|
G |
Ikbke |
inhibitor of nuclear factor kappa B kinase subunit epsilon |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of IKBKE mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of IKBKE mRNA |
CTD |
PMID:16357179 |
|
NCBI chr13:48,031,325...48,056,394
Ensembl chr13:48,031,410...48,056,394
|
|
G |
Irf2bp2 |
interferon regulatory factor 2 binding protein 2 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of IRF2BP2 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of IRF2BP2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:59,497,021...59,502,298
Ensembl chr19:59,499,876...59,502,161
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of JUND mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of JUND mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:20,485,028...20,486,707
Ensembl chr16:20,485,029...20,486,707
|
|
G |
Kdm3a |
lysine demethylase 3A |
increases expression |
ISO |
motexafin gadolinium results in increased expression of KDM3A mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:99,503,160...99,547,315
Ensembl chr 4:99,503,176...99,546,905
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of MDM2 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of MDM2 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Mob1a |
MOB kinase activator 1A |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of MOB1A mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of MOB1A mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 4:115,024,927...115,041,904
Ensembl chr 4:115,024,927...115,041,899
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions |
ISO |
[Zinc co-treated with motexafin gadolinium] results in increased expression of MT1A mRNA |
CTD |
PMID:15867382 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of MT2A mRNA] motexafin gadolinium results in increased expression of MT2A mRNA |
CTD |
PMID:15867382 PMID:16357179 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of MYD88 mRNA motexafin gadolinium results in decreased expression of MYD88 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:128,022,512...128,027,462
Ensembl chr 8:128,022,473...128,026,841
|
|
G |
Nadk |
NAD kinase |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of NADK mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of NADK mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:172,984,930...173,015,505
Ensembl chr 5:172,986,291...173,015,494
|
|
G |
Nf1 |
neurofibromin 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of NF1 mRNA motexafin gadolinium results in increased expression of NF1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:66,732,460...66,928,706
Ensembl chr10:66,690,133...66,928,903
|
|
G |
Nisch |
nischarin |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of NISCH mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:7,254,372...7,290,670
Ensembl chr16:7,254,974...7,290,561
|
|
G |
Nr1d2 |
nuclear receptor subfamily 1, group D, member 2 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of NR1D2 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of NR1D2 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr15:8,730,871...8,757,165
Ensembl chr15:8,730,871...8,757,165
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of P4HB mRNA] motexafin gadolinium results in increased expression of P4HB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:109,736,459...109,748,070
Ensembl chr10:109,736,458...109,747,987
|
|
G |
Pdcd11 |
programmed cell death 11 |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of PDCD11 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:266,866,931...266,908,042
Ensembl chr 1:266,866,931...266,908,042
|
|
G |
Pdcd4 |
programmed cell death 4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PDCD4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PDCD4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:274,616,625...274,648,204
Ensembl chr 1:274,625,224...274,648,204
|
|
G |
Pdcd5 |
programmed cell death 5 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of PDCD5 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of PDCD5 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:91,173,473...91,178,801
Ensembl chr 1:91,173,473...91,178,801 Ensembl chr 1:91,173,473...91,178,801
|
|
G |
Pfkfb3 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PFKFB3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PFKFB3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr17:70,632,778...70,713,736
Ensembl chr17:70,684,134...70,713,726
|
|
G |
Pfkfb4 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PFKFB4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PFKFB4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:117,733,347...117,776,525
Ensembl chr 8:117,737,117...117,775,386
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PGK1 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of PGK1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr X:77,263,399...77,279,373
Ensembl chr X:77,263,359...77,279,367
|
|
G |
Phtf2 |
putative homeodomain transcription factor 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of PHTF2 mRNA] motexafin gadolinium results in increased expression of PHTF2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:10,823,191...10,938,273
Ensembl chr 4:10,823,281...10,938,318
|
|
G |
Pias1 |
protein inhibitor of activated STAT, 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of PIAS1 mRNA] motexafin gadolinium results in increased expression of PIAS1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:67,771,720...67,869,015
Ensembl chr 8:67,771,720...67,869,019
|
|
G |
Pik3ip1 |
phosphoinositide-3-kinase interacting protein 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PIK3IP1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PIK3IP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:83,559,397...83,572,481
Ensembl chr14:83,560,541...83,572,473
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PMAIP1 mRNA motexafin gadolinium results in increased expression of PMAIP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
|
|
G |
Prkacb |
protein kinase cAMP-activated catalytic subunit beta |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PRKACB mRNA motexafin gadolinium results in increased expression of PRKACB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:252,602,197...252,691,886
Ensembl chr 2:252,605,307...252,691,886
|
|
G |
Prkcd |
protein kinase C, delta |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of PRKCD mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:6,655,131...6,675,746
Ensembl chr16:6,655,120...6,675,746
|
|
G |
Prkd2 |
protein kinase D2 |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of PRKD2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:78,767,911...78,796,223
Ensembl chr 1:78,767,911...78,796,231
|
|
G |
Prkdc |
protein kinase, DNA-activated, catalytic subunit |
increases expression |
ISO |
motexafin gadolinium results in increased expression of PRKDC mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:89,293,547...89,510,948
Ensembl chr11:89,293,696...89,510,871
|
|
G |
Ptrh2 |
peptidyl-tRNA hydrolase 2 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of PTRH2 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of PTRH2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:74,002,151...74,012,182
Ensembl chr10:74,002,151...74,012,159
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of RB1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of RB1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rcbtb2 |
RCC1 and BTB domain containing protein 2 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of RCBTB2 mRNA motexafin gadolinium results in decreased expression of RCBTB2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr15:55,029,388...55,074,728
Ensembl chr15:55,034,033...55,073,437
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of RELB mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of RELB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:80,517,081...80,545,019
Ensembl chr 1:80,517,411...80,544,825
|
|
G |
Rnf19b |
ring finger protein 19B |
increases expression |
ISO |
motexafin gadolinium results in increased expression of RNF19B mRNA |
CTD |
PMID:15867382 |
|
NCBI chr 5:147,246,032...147,270,892
Ensembl chr 5:147,246,037...147,270,957
|
|
G |
Selenow |
selenoprotein W |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SELENOW mRNA motexafin gadolinium results in increased expression of SELENOW mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:77,530,692...77,535,765
Ensembl chr 1:77,533,148...77,535,681 Ensembl chr 1:77,533,148...77,535,681
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions increases expression |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SESN2 mRNA; [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SESN2 mRNA; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SESN2 mRNA] motexafin gadolinium results in increased expression of SESN2 mRNA |
CTD |
PMID:16357179 PMID:20530418 |
|
NCBI chr 5:150,684,891...150,703,846
Ensembl chr 5:150,684,133...150,704,117
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC16A1 mRNA] motexafin gadolinium results in increased expression of SLC16A1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:207,108,552...207,129,352
Ensembl chr 2:207,108,552...207,128,554
|
|
G |
Slc16a6 |
solute carrier family 16, member 6 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SLC16A6 mRNA motexafin gadolinium results in increased expression of SLC16A6 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:97,733,701...97,758,723
Ensembl chr10:97,735,548...97,756,521
|
|
G |
Slc1a4 |
solute carrier family 1 member 4 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC1A4 mRNA] motexafin gadolinium results in increased expression of SLC1A4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:104,582,884...104,612,417
Ensembl chr14:104,581,190...104,612,597
|
|
G |
Slc30a1 |
solute carrier family 30 member 1 |
multiple interactions increases expression |
ISO |
[Zinc co-treated with motexafin gadolinium] results in increased expression of SLC30A1 mRNA; motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC30A1 mRNA]; Zinc Acetate affects the reaction [motexafin gadolinium results in increased expression of SLC30A1 mRNA] |
CTD |
PMID:15867382 PMID:16357179 |
|
NCBI chr13:110,677,810...110,681,683
Ensembl chr13:110,677,810...110,681,683
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC38A2 mRNA]; Zinc Acetate affects the reaction [motexafin gadolinium results in increased expression of SLC38A2 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 7:138,088,654...138,100,869
Ensembl chr 7:138,088,649...138,100,841
|
|
G |
Slc39a10 |
solute carrier family 39 member 10 |
multiple interactions affects expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC39A10 mRNA motexafin gadolinium affects the expression of SLC39A10 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:59,947,562...60,070,549
Ensembl chr 9:60,021,534...60,070,552
|
|
G |
Slc39a14 |
solute carrier family 39 member 14 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of SLC39A14 mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC39A14 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr15:51,982,872...52,029,841
Ensembl chr15:51,982,982...52,029,816
|
|
G |
Slc39a9 |
solute carrier family 39, member 9 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of SLC39A9 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SLC39A9 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:104,291,001...104,326,553
Ensembl chr 6:104,291,071...104,329,872
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC3A2 mRNA motexafin gadolinium results in increased expression of SLC3A2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:224,906,566...224,921,029
Ensembl chr 1:224,906,554...224,921,092
|
|
G |
Slc43a1 |
solute carrier family 43 member 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SLC43A1 mRNA motexafin gadolinium results in increased expression of SLC43A1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:72,238,796...72,265,023
Ensembl chr 3:72,238,981...72,264,466
|
|
G |
Slc7a1 |
solute carrier family 7 member 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC7A1 mRNA motexafin gadolinium results in increased expression of SLC7A1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr12:8,032,775...8,108,972
Ensembl chr12:8,032,809...8,108,972
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of SLC7A11 mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC7A11 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:139,453,774...139,528,479
Ensembl chr 2:139,453,774...139,528,162
|
|
G |
Smarca4 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of SMARCA4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SMARCA4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:22,648,323...22,739,468
Ensembl chr 8:22,648,323...22,739,468
|
|
G |
Smarca5 |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of SMARCA5 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SMARCA5 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:30,936,703...30,969,454
Ensembl chr19:30,936,703...30,969,454
|
|
G |
Tagap |
T-cell activation RhoGTPase activating protein |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of TAGAP mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TAGAP mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:47,493,990...47,503,492
Ensembl chr 1:47,493,994...47,502,952
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of TFRC mRNA] motexafin gadolinium results in increased expression of TFRC mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
|
|
G |
Tnfaip8 |
TNF alpha induced protein 8 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of TNFAIP8 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TNFAIP8 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr18:44,664,310...44,779,914
Ensembl chr18:44,716,226...44,779,914
|
|
G |
Tnfrsf17 |
TNF receptor superfamily member 17 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TNFRSF17 mRNA motexafin gadolinium results in decreased expression of TNFRSF17 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:4,252,097...4,258,335
Ensembl chr10:4,251,941...4,257,868
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of TNFRSF1A mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TNFRSF1A mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:157,864,905...157,877,634
Ensembl chr 4:157,864,969...157,877,633
|
|
G |
Tnfsf8 |
TNF superfamily member 8 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of TNFSF8 mRNA] motexafin gadolinium results in increased expression of TNFSF8 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:79,664,779...79,691,547
Ensembl chr 5:79,664,765...79,691,258
|
|
G |
Tnip2 |
TNFAIP3 interacting protein 2 |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of TNIP2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:81,487,934...81,505,889
Ensembl chr14:81,488,008...81,504,686
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein; Acetylcysteine inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein]; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] |
CTD |
PMID:20530418 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of TRIB3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TRIB3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:147,814,056...147,819,650
Ensembl chr 3:147,813,473...147,819,571
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of TXNRD1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TXNRD1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of VEGFA mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of VEGFA mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vhl |
von Hippel-Lindau tumor suppressor |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of VHL mRNA] motexafin gadolinium results in increased expression of VHL mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:145,580,869...145,587,835
Ensembl chr 4:145,580,799...145,587,845
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
ABCG2 protein affects the reaction [3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester results in decreased transport of pheophorbide a]; ABCG2 protein affects the reaction [Mifepristone results in decreased transport of pheophorbide a] |
CTD |
PMID:30217652 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
|
G |
Anpep |
alanyl aminopeptidase, membrane |
decreases activity |
ISO |
Porphyrins analog results in decreased activity of ANPEP protein |
CTD |
PMID:19189318 |
|
NCBI chr 1:141,561,364...141,604,249
Ensembl chr 1:141,561,334...141,604,273
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
Porphyrins results in increased expression of BAX mRNA |
CTD |
PMID:26468117 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
ISO |
Porphyrins results in increased expression of BCL2 mRNA |
CTD |
PMID:26468117 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Casp3 |
caspase 3 |
increases expression |
ISO |
Porphyrins results in increased expression of CASP3 mRNA |
CTD |
PMID:26468117 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
increases expression |
ISO |
Porphyrins results in increased expression of CASP8 mRNA |
CTD |
PMID:26468117 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cat |
catalase |
decreases expression increases expression |
ISO |
Porphyrins results in decreased expression of CAT protein Porphyrins results in increased expression of CAT mRNA |
CTD |
PMID:26468117 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression |
ISO |
Porphyrins results in decreased expression of GPX1 mRNA |
CTD |
PMID:26468117 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
increases expression |
ISO |
Porphyrins results in increased expression of KEAP1 mRNA |
CTD |
PMID:31385236 |
|
NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
increases expression |
ISO |
Porphyrins results in increased expression of NFE2L2 mRNA |
CTD |
PMID:31385236 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression decreases expression |
ISO |
Porphyrins results in increased expression of SOD1 mRNA Porphyrins results in decreased expression of SOD1 protein |
CTD |
PMID:26468117 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression decreases expression |
ISO |
Porphyrins results in increased expression of SOD2 mRNA Porphyrins results in decreased expression of SOD2 protein |
CTD |
PMID:26468117 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Tspo |
translocator protein |
affects transport |
EXP |
TSPO protein affects the transport of Porphyrins |
CTD |
PMID:11020479 |
|
NCBI chr 7:124,460,358...124,470,610
Ensembl chr 7:124,460,358...124,470,609
|
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions decreases chemical synthesis |
ISO |
ATP7B gene mutant form promotes the reaction [Copper results in decreased abundance of protoporphyrin IX] ATP7B gene mutant form results in decreased chemical synthesis of protoporphyrin IX |
CTD |
PMID:19888908 |
|
NCBI chr16:74,865,516...74,944,935
Ensembl chr16:74,865,516...74,945,286
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases activity increases activity |
EXP ISO |
Doxorubicin promotes the reaction [protoporphyrin IX results in increased activity of CASP3 protein] protoporphyrin IX results in decreased activity of CASP3 protein |
CTD |
PMID:16051694 PMID:18845130 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
decreases activity |
ISO |
protoporphyrin IX results in decreased activity of CASP8 protein |
CTD |
PMID:16051694 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
EXP |
protoporphyrin IX inhibits the reaction [[Sulfasalazine results in increased expression of HMOX1 protein] which results in increased expression of CDKN1A protein] |
CTD |
PMID:19234301 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
EXP |
protoporphyrin IX affects the localization of CYCS protein |
CTD |
PMID:18845130 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO |
protoporphyrin IX results in decreased expression of EGFR protein |
CTD |
PMID:23624237 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
affects localization |
ISO |
protoporphyrin IX affects the localization of EPAS1 protein |
CTD |
PMID:23624237 |
|
NCBI chr 6:10,306,508...10,385,239
Ensembl chr 6:10,306,405...10,387,265
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of protoporphyrin IX |
CTD |
PMID:29906468 |
|
NCBI chr18:59,941,992...59,975,192
Ensembl chr18:59,941,992...59,975,192
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
protoporphyrin IX results in increased expression of FOS mRNA |
CTD |
PMID:10381381 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Gucy1a1 |
guanylate cyclase 1 soluble subunit alpha 1 |
multiple interactions |
ISO |
Polysorbates promotes the reaction [protoporphyrin IX results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; protoporphyrin IX results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein] |
CTD |
PMID:22171090 |
|
NCBI chr 2:181,045,694...181,103,321
Ensembl chr 2:181,045,703...181,102,918
|
|
G |
Gucy1b1 |
guanylate cyclase 1 soluble subunit beta 1 |
multiple interactions |
ISO |
Polysorbates promotes the reaction [protoporphyrin IX results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein]]; protoporphyrin IX results in increased activity of [GUCY1A1 protein binds to GUCY1B1 protein] |
CTD |
PMID:22171090 |
|
NCBI chr 2:180,976,939...181,026,001
Ensembl chr 2:180,976,939...181,026,024
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions affects localization increases degradation decreases activity |
ISO |
Adenosine Triphosphate inhibits the reaction [protoporphyrin IX results in decreased activity of HIF1A protein] protoporphyrin IX affects the localization of HIF1A protein protoporphyrin IX results in increased degradation of HIF1A protein |
CTD |
PMID:23624237 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions decreases activity |
EXP |
protoporphyrin IX inhibits the reaction [[Sulfasalazine results in increased expression of HMOX1 protein] which results in increased expression of CDKN1A protein]; protoporphyrin IX inhibits the reaction [Hemin results in increased activity of HMOX1 protein] protoporphyrin IX results in decreased activity of HMOX1 protein |
CTD |
PMID:18845130 PMID:19234301 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
decreases response to substance |
ISO |
HSP90AA1 protein results in decreased susceptibility to protoporphyrin IX |
CTD |
PMID:23624237 |
|
NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression |
ISO |
protoporphyrin IX results in decreased expression of MMP2 mRNA; protoporphyrin IX results in decreased expression of MMP2 protein |
CTD |
PMID:23624237 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
protoporphyrin IX inhibits the reaction [Plant Extracts inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] |
CTD |
PMID:21827494 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases expression |
ISO |
protoporphyrin IX results in decreased expression of NOS3 protein |
CTD |
PMID:23624237 |
|
NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
NR1I3 protein affects the reaction [oxadiazon results in increased abundance of protoporphyrin IX] |
CTD |
PMID:26710982 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
decreases expression |
ISO |
protoporphyrin IX results in decreased expression of NR3C1 protein |
CTD |
PMID:23624237 |
|
NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
|
|
G |
Plat |
plasminogen activator, tissue type |
decreases expression |
ISO |
protoporphyrin IX results in decreased expression of PLAT protein |
CTD |
PMID:23624237 |
|
NCBI chr16:74,098,263...74,122,897
Ensembl chr16:74,098,260...74,122,889
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
protoporphyrin IX inhibits the reaction [Plant Extracts inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]] |
CTD |
PMID:21827494 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
decreases expression |
ISO |
protoporphyrin IX results in decreased expression of SLC2A1 mRNA |
CTD |
PMID:23624237 |
|
NCBI chr 5:138,154,677...138,182,897
Ensembl chr 5:138,154,673...138,182,897
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
protoporphyrin IX inhibits the reaction [16-(4-fluorophenoxy)lipoxin A4 inhibits the reaction [TNF results in increased expression of VCAM1 protein]] |
CTD |
PMID:15901601 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tspo |
translocator protein |
decreases abundance |
EXP |
TSPO protein results in decreased abundance of protoporphyrin IX |
CTD |
PMID:11020479 |
|
NCBI chr 7:124,460,358...124,470,610
Ensembl chr 7:124,460,358...124,470,609
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
protoporphyrin IX inhibits the reaction [16-(4-fluorophenoxy)lipoxin A4 inhibits the reaction [TNF results in increased expression of VCAM1 protein]] |
CTD |
PMID:15901601 |
|
NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
|
|
|
G |
Cpox |
coproporphyrinogen oxidase |
increases chemical synthesis multiple interactions |
ISO |
CPOX protein results in increased chemical synthesis of protoporphyrinogen Mercury inhibits the reaction [CPOX protein results in increased chemical synthesis of protoporphyrinogen]; TGFB1 protein promotes the reaction [CPOX protein results in increased chemical synthesis of protoporphyrinogen] |
CTD |
PMID:11248690 PMID:19339664 |
|
NCBI chr11:44,039,665...44,049,648
Ensembl chr11:44,039,669...44,049,648
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
TGFB1 protein promotes the reaction [CPOX protein results in increased chemical synthesis of protoporphyrinogen] |
CTD |
PMID:11248690 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
|
G |
Areg |
amphiregulin |
increases expression |
ISO |
Protoporphyrins results in increased expression of AREG protein |
CTD |
PMID:19267999 |
|
NCBI chr14:18,521,921...18,531,179
Ensembl chr14:18,521,930...18,531,179
|
|
G |
Btc |
betacellulin |
increases expression |
ISO |
Protoporphyrins results in increased expression of BTC protein |
CTD |
PMID:19267999 |
|
NCBI chr14:18,231,854...18,270,621
Ensembl chr14:18,231,860...18,272,484
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Protoporphyrins results in increased expression of EREG protein |
CTD |
PMID:19267999 |
|
NCBI chr14:18,577,620...18,591,395
Ensembl chr14:18,576,355...18,591,394
|
|
|
G |
Ankrd1 |
ankyrin repeat domain 1 |
multiple interactions decreases expression |
ISO |
verteporfin inhibits the reaction [YAP1 protein results in increased expression of ANKRD1 mRNA] Verteporfin inhibits the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of ANKRD1 mRNA] verteporfin results in decreased expression of ANKRD1 mRNA |
CTD |
PMID:29725256 PMID:29893953 |
|
NCBI chr 1:254,726,985...254,745,673
Ensembl chr 1:254,726,969...254,735,548
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
Verteporfin inhibits the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of BIRC5 mRNA] |
CTD |
PMID:29893953 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Verteporfin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL2 protein] |
CTD |
PMID:31812773 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
Verteporfin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL5 protein] |
CTD |
PMID:31812773 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions decreases expression |
ISO |
Verteporfin inhibits the reaction [YAP1 protein results in increased expression of CCN1 mRNA] Verteporfin inhibits the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of CCN1 mRNA] Verteporfin results in decreased expression of CCN1 mRNA |
CTD |
PMID:29725256 PMID:29893953 |
|
NCBI chr 2:251,529,354...251,532,312
Ensembl chr 2:251,529,354...251,532,312
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression multiple interactions |
ISO |
Verteporfin results in decreased expression of CCN2 mRNA Verteporfin inhibits the reaction [YAP1 protein results in increased expression of CCN2 mRNA] |
CTD |
PMID:29725256 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions |
ISO |
Verteporfin inhibits the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of CCNA2 mRNA] |
CTD |
PMID:29893953 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
Verteporfin inhibits the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of CCNB1 mRNA] |
CTD |
PMID:29893953 |
|
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
|
|
G |
Cma1 |
chymase 1 |
multiple interactions |
ISO |
Verteporfin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CMA1 protein] |
CTD |
PMID:31812773 |
|
NCBI chr15:34,601,037...34,603,819
Ensembl chr15:34,601,037...34,603,819
|
|
G |
Csf3 |
colony stimulating factor 3 |
multiple interactions |
ISO |
Verteporfin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CSF3 protein] |
CTD |
PMID:31812773 |
|
NCBI chr10:86,616,785...86,619,160
Ensembl chr10:86,616,785...86,619,157
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
Verteporfin inhibits the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of CYP2B10 mRNA] |
CTD |
PMID:29893953 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
multiple interactions |
ISO |
Verteporfin inhibits the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of CYP2C55 mRNA] |
CTD |
PMID:29893953 |
|
NCBI chr 1:258,074,797...258,139,176
Ensembl chr 1:258,074,860...258,139,176
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
verteporfin results in increased expression of HMOX1 protein |
CTD |
PMID:16462769 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[EVP 4593 co-treated with Verteporfin] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 mRNA]; Verteporfin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 mRNA] Verteporfin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 mRNA]; Verteporfin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 protein] |
CTD |
PMID:31812773 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Jak1 |
Janus kinase 1 |
multiple interactions decreases expression |
ISO |
[Verteporfin co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in decreased expression of JAK1 protein Verteporfin results in decreased expression of JAK1 protein |
CTD |
PMID:31812773 |
|
NCBI chr 5:119,982,503...120,091,452
Ensembl chr 5:119,982,943...120,083,904
|
|
G |
Jak2 |
Janus kinase 2 |
decreases expression multiple interactions |
ISO |
Verteporfin results in decreased expression of JAK2 protein [Verteporfin co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in decreased expression of JAK2 protein |
CTD |
PMID:31812773 |
|
NCBI chr 1:247,398,667...247,457,521
Ensembl chr 1:247,398,598...247,458,509
|
|
G |
Mcm2 |
minichromosome maintenance complex component 2 |
multiple interactions |
ISO |
Verteporfin inhibits the reaction [1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in increased expression of MCM2 mRNA] |
CTD |
PMID:29893953 |
|
NCBI chr 4:120,825,699...120,840,221
Ensembl chr 4:120,825,699...120,840,111
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
Verteporfin results in increased cleavage of PARP1 protein |
CTD |
PMID:31494105 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[Verteporfin co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in decreased expression of RELA protein; Verteporfin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of and results in increased phosphorylation of RELA protein] |
CTD |
PMID:31812773 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
decreases expression multiple interactions |
ISO |
Verteporfin results in decreased expression of STAT1 protein Verteporfin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of and results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:31812773 |
|
NCBI chr 9:54,287,540...54,327,958
Ensembl chr 9:54,287,541...54,484,533
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions decreases expression |
ISO |
Verteporfin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of and results in increased phosphorylation of STAT3 protein] Verteporfin results in decreased expression of STAT3 protein |
CTD |
PMID:31812773 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Tead1 |
TEA domain transcription factor 1 |
multiple interactions |
ISO |
Verteporfin inhibits the reaction [YAP1 protein binds to TEAD1 protein] |
CTD |
PMID:29893953 |
|
NCBI chr 1:177,495,500...177,714,795
Ensembl chr 1:177,495,782...177,707,061
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Verteporfin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]; Verteporfin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein] [EVP 4593 co-treated with Verteporfin] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]; Verteporfin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA] |
CTD |
PMID:31812773 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Yap1 |
Yes1 associated transcriptional regulator |
multiple interactions decreases expression |
ISO |
Verteporfin inhibits the reaction [YAP1 protein results in increased expression of ANKRD1 mRNA]; Verteporfin inhibits the reaction [YAP1 protein results in increased expression of CCN1 mRNA]; Verteporfin inhibits the reaction [YAP1 protein results in increased expression of CCN2 mRNA] Verteporfin results in decreased expression of YAP1 protein Verteporfin inhibits the reaction [YAP1 protein binds to TEAD1 protein] |
CTD |
PMID:29725256 PMID:29893953 PMID:31494105 |
|
NCBI chr 8:6,133,014...6,204,240
Ensembl chr 8:6,135,493...6,203,579
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO EXP |
zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]]; zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]] zinc protoporphyrin inhibits the reaction [ADIPOQ protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]] |
CTD |
PMID:20052772 PMID:20861358 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
[zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]]; [zinc protoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [neferine inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:20523338 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
zinc protoporphyrin inhibits the reaction [olprinone results in increased activity of AKT1 protein] |
CTD |
PMID:19387321 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alad |
aminolevulinate dehydratase |
affects abundance |
ISO |
ALAD gene SNP affects the abundance of zinc protoporphyrin |
CTD |
PMID:25963508 |
|
NCBI chr 5:78,368,867...78,379,206
Ensembl chr 5:78,368,867...78,379,346
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; ALB protein inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]]; ALB protein inhibits the reaction [zinc protoporphyrin results in increased expression of HMOX1 protein] zinc protoporphyrin inhibits the reaction [ALB protein results in increased expression of HMOX1 protein]; zinc protoporphyrin promotes the reaction [ALB protein results in increased expression of TIMP1 protein] |
CTD |
PMID:19376148 PMID:21163135 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Alms1 |
ALMS1, centrosome and basal body associated protein |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of ALMS1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 4:117,371,544...117,472,310
Ensembl chr 4:117,371,659...117,472,198
|
|
G |
Ap2a1 |
adaptor related protein complex 2 subunit alpha 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of AP2A1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 1:100,896,582...100,926,443
Ensembl chr 1:100,896,947...100,926,335
|
|
G |
Ap3d1 |
adaptor related protein complex 3 subunit delta 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of AP3D1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 7:11,838,639...11,873,992
Ensembl chr 7:11,838,639...11,873,984
|
|
G |
Asf1a |
anti-silencing function 1A histone chaperone |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in decreased expression of ASF1A mRNA |
CTD |
PMID:22839698 |
|
NCBI chr20:34,894,419...34,909,265
Ensembl chr20:34,894,419...34,909,265
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO EXP |
zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; zinc protoporphyrin inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in increased expression of BAX protein]] zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in increased expression of BAX mRNA]] zinc protoporphyrin inhibits the reaction [Cisplatin results in increased expression of BAX protein] |
CTD |
PMID:22763982 PMID:27523796 PMID:27815112 PMID:32621855 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO EXP |
zinc protoporphyrin inhibits the reaction [2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; zinc protoporphyrin inhibits the reaction [resveratrol inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]] zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]] |
CTD |
PMID:22763982 PMID:27523796 PMID:32621855 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions increases expression |
EXP ISO |
zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in increased expression of BCL2L1 protein] zinc protoporphyrin results in increased expression of BCL2L1 protein |
CTD |
PMID:20357190 PMID:27829220 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bcl2l11 |
BCL2 like 11 |
increases expression |
ISO |
zinc protoporphyrin results in increased expression of BCL2L11 protein |
CTD |
PMID:27829220 |
|
NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
multiple interactions |
ISO |
zinc protoporphyrin analog inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of BIRC3 protein] |
CTD |
PMID:18508827 |
|
NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions |
EXP |
zinc protoporphyrin inhibits the reaction [monophosphoryl lipid A results in increased expression of CALCA mRNA] |
CTD |
PMID:11738242 |
|
NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
|
|
G |
Cand1 |
cullin-associated and neddylation-dissociated 1 |
multiple interactions |
ISO |
[lead acetate co-treated with zinc protoporphyrin] results in increased expression of CAND1 mRNA |
CTD |
PMID:22839698 |
|
NCBI chr 7:62,124,362...62,162,451
Ensembl chr 7:62,124,362...62,162,453
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage decreases activity |
ISO EXP |
zinc protoporphyrin inhibits the reaction [[Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [Resveratrol inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]]; zinc protoporphyrin inhibits the reaction [sesamol inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]]; zinc protoporphyrin promotes the reaction [T-2 Toxin results in increased activity of CASP3 protein] zinc protoporphyrin results in increased cleavage of CASP3 protein zinc protoporphyrin inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [Curcumin inhibits the reaction [quinocetone results in increased activity of CASP3 protein]]; zinc protoporphyrin inhibits the reaction [FASLG protein results in increased activity of CASP3 protein]; zinc protoporphyrin inhibits the reaction [FASLG protein results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [rutecarpine inhibits the reaction [tert-Butylhydroperoxide results in increased activity of CASP3 protein]]; zinc protoporphyrin promotes the reaction [arsenic trioxide results in increased activity of CASP3 protein]; zinc protoporphyrin promotes the reaction [quinocetone results in increased activity of CASP3 protein] zinc protoporphyrin inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [cobaltiprotoporphyrin results in decreased expression of CASP3 protein]; zinc protoporphyrin inhibits the reaction [Tadalafil inhibits the reaction [Cisplatin results in increased expression of CASP3 mRNA]]; zinc protoporphyrin promotes the reaction [[[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] co-treated with Ethanol] results in increased cleavage of CASP3 protein]; zinc protoporphyrin promotes the reaction [[[Oxygen deficiency co-treated with Blood Glucose deficiency] co-treated with [Oxygen co-treated with Blood Glucose]] results in increased cleavage of CASP3 protein] zinc protoporphyrin results in decreased activity of CASP3 protein |
CTD |
PMID:16051694 PMID:17928392 PMID:20357190 PMID:21295052 PMID:22763982 PMID:25003661 PMID:26747958 PMID:27375190 PMID:27815112 PMID:28025122 PMID:29432840 PMID:30261164 PMID:32621855 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
zinc protoporphyrin inhibits the reaction [FASLG protein results in increased activity of CASP8 protein] |
CTD |
PMID:16051694 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
 |